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Transfer learning is a sub-field of statistical modeling and machine learning. It 
refers to methods that integrate the knowledge of other domains (called source domains) 
and the data of the target domain in a mathematically rigorous and intelligent way, to 
develop a better model for the target domain than a model using the data of the target 
domain alone. While transfer learning is a promising approach in various application 
domains, my dissertation research focuses on the particular application in health care, 
including telemonitoring of Parkinson’s Disease (PD) and radiomics for glioblastoma. 
The first topic is a Mixed Effects Transfer Learning (METL) model that can flexibly 
incorporate mixed effects and a general-form covariance matrix to better account for 
similarity and heterogeneity across subjects. I further develop computationally efficient 
procedures to handle unknown parameters and large covariance structures. Domain 
relations, such as domain similarity and domain covariance structure, are automatically 
quantified in the estimation steps. I demonstrate METL in an application of smartphone-
based telemonitoring of PD.  
The second topic focuses on an MRI-based transfer learning algorithm for non-
invasive surgical guidance of glioblastoma patients. Limited biopsy samples per patient 
create a challenge to build a patient-specific model for glioblastoma. A transfer learning 
framework helps to leverage other patient’s knowledge for building a better predictive 
model. When modeling a target patient, not every patient’s information is helpful. 
Deciding the subset of other patients from which to transfer information to the modeling 
of the target patient is an important task to build an accurate predictive model. I define the 
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subset of “transferrable” patients as those who have a positive rCBV-cell density 
correlation, because a positive correlation is confirmed by imaging theory and the its 
respective literature.   
The last topic is a Privacy-Preserving Positive Transfer Learning (P3TL) model.  
Although negative transfer has been recognized as an important issue by the transfer 
learning research community, there is a lack of theoretical studies in evaluating the risk 
of negative transfer for a transfer learning method and identifying what causes the 
negative transfer. My work addresses this issue. Driven by the theoretical insights, I 
extend Bayesian Parameter Transfer (BPT) to a new method, i.e., P3TL. The unique 
features of P3TL include intelligent selection of patients to transfer in order to avoid 
negative transfer and maintain patient privacy. These features make P3TL an excellent 
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Transfer learning is a basic ability of human beings when learning a new skill or 
accomplishing a new task. It refers to the ability that people can effectively extend 
knowledge previously learned in one situation to solve new situations that have never been 
encountered before quickly or with better solutions. For example, suppose two people are 
learning to play golf. One person has no previous experience playing any other sports, and 
the other person is experienced with another sport like tennis. The latter person will be 
likely to learn golf in a more efficient manner by applying previously learned knowledge 
of other sports. Transfer learning, as a subfield in statistical modeling and machine learning, 
has a similar nature. It refers to methods that integrate the knowledge of other domains 
(called the source domains) and the data of the target domain in a mathematically rigorous 
and intelligent way, to develop a better model for the target domain than a model using the 
data of the target domain alone.  
When modeling a target domain, classic statistical models without transfer learning 
typically handles the situation in two ways: One is the so-called single learning, which uses 
the data of the target domain alone to build a model. The other is the so-called one-model-
fits-all approach, which pools the data of the source and target domains together to build a 
model. The first approach is limited in the sense that it may suffer from small sample size 
of the target domain. The second approach is also sub-optimal because it does not account 
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for domain differences. Transfer learning mitigates the limitations of the two 
aforementioned classic approaches by leveraging the information/knowledge in the source 
domains and meanwhile considering the difference between the source and target domains.  
While transfer learning is a promising approach in various application domains, my 
dissertation research focuses on the particular application in health care. Next, I give two 
examples of why transfer learning is highly desirable in sub-areas of the health care 
application:  
Telemonitoring: This is an emerging area in health care that focuses on using 
electronic devices or smartphones to remotely monitor patients and their disease 
progression. This saves tremendous cost as the patient does not need to come to the clinic 
in person to get assessment, and also allows for more frequent, close monitoring of the 
disease and adjusts treatment decisions. However, every patient is different so a patient- 
specific model that links telemonitoring signals and a disease severity metric is needed. 
Each patient has only limited samples; also, a model trained using only a few samples to 
achieve satisfactory accuracy is desirable because this means that the model can be 
deployed sooner to benefit the patient. To tackle the challenge of limited sample sizes for 
each patient, transfer learning is a much-needed approach to leverage other patients’ 
information to integrate with each target patient’s specific data.  
Radiomics: This is also an important area in health care that bridges phenotypic 
radiologic images with underlying omics markers of a disease – typically cancer. Taking 
glioblastoma—a fatal brain cancer, as an example, there is substantial intra-tumor  
heterogeneity in omics markers (e.g., cancer cell density, copy number variants, etc), which 
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leads to sub-optimal treatment, recurrence, and poor survival. Conventionally, surgical 
biopsy is used to take samples from a few different locations of the tumor to understand 
the spatial diversity of omics markers. However, biopsy is highly invasive and therefore 
only a limited number of samples are feasible, which is far from satisfactory for capturing 
the spatially densely-varying omics heterogeneity. Imaging, on the other hand, is non-
invasive, and provides spatial characterization for the entire tumor. If one could build a 
model that links local image features with an omics marker, namely a radiomics model, 
this model could be used to generate a predictive map of the omics marker for the entire 
tumor. The map can be further used to guide treatment decisions with precision. However, 
every patient is different and a patient-specific radiomics model needs to be trained, which 
suffers from limited sample size due to the small number of biopsy samples included in the 
training set. Transfer learning is a desirable approach to leverage other patients’ 
information to integrate with each target patient’s specific data.  
 
1.2 State of the Art 
Transfer Learning is a sub-field of statistical modeling and machine learning for 
which the existing methods fall into three major categories: instance transfer, feature 
transfer, and parameter transfer. Instance transfer reuses data from the source domain to 
augment the data in the target domain. For example, Dai et al. (2007) proposed a boosting 
algorithm called TrAdaBoost to iteratively identify samples in the old domains that are 
helpful for modeling the new domain. Chattopadhyay et al. (2012) proposed a multisource 
domain adaptation approach that adopted a reweighting scheme to identify weighted 
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samples in the source domains. Lin et al. (2013) employed a bootstrapping-based double-
selection process to reduce the impact of reusing irrelevant data in the source domains.  
Feature transfer aims to find a joint feature representation shared by the source and 
target domains. For example, Evgeniou and Pontil (2007) proposed a shared mapping 
technique across the domains from the original high-dimensional predictor space to a low-
dimensional feature space. Nonlinear mapping was also studied by Jebara (2004) for 
Support Vector Machines (SVMs). Pan et al. (2010) proposed a spectral feature alignment 
(SFA) algorithm to discover common latent features with the same marginal distribution 
across the source and target domains. Ruckert and Kramer (2008) and Gong et al. (2012) 
proposed kernel based techniques to adjust learning bias by choosing a suitable kernel for 
the target domain.  
Parameter transfer assumes that closely related domains should have similar 
parameters in their respective models, and encourages source and target domains to share 
some model parameters. For example, Liu et al. (2009) adopted L21-norm regularization 
for selection of the same predictors across the domains. Tommasi et al. (2010) proposed to 
share the Support Vector Machines (SVM) hyperplane information of each source domain 
with the target domain. Argyriou et al. (2008) proposed to use a sparse representation based 
𝑙1 regularization to enable joint parameter estimation across related domains. Evgeniou and 
Pontil (2004) also studied regularized approaches for nonlinear models. In addition to 
regularization, Bayesian statistics provide a framework for the model parameters across 
the domains by assuming the same prior distribution. (Lawrence and Platt 2004; 
Schwaighofer et al. 2004; Bonilla et al. 2008). 
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The limitations of existing transfer learning methods are as follows: 
• Lack of mixed effects models: Mixed effects models are a category of 
statistical models that allow for relaxing the IID (Identically and Independently 
Distributed) assumption most other models have to assume, and thus making it 
possible to take into account more complicated data structures. These models 
are particularly useful in the modeling of each patient in the telemonitoring 
application, where repeated measurements are made on the same patient so that 
there is dependency between the data points violating the IID assumption. 
However, in the transfer learning literature, there is little work on mixed effects 
models. 
• Lack of privacy-preserving consideration: Existing transfer learning 
methods fall short in fulfilling a special need in health care applications, i.e., 
how to preserve patient privacy in transfer learning. Most existing methods 
need to “see” the data of other patients when modeling a target patient, which 
violates privacy preservation. Privacy-preserving is an area of research in 
computer science and engineering, with classic techniques including 
differential privacy (DP) and cryptography. DP is a well-known category 
intended to achieve security on private databases by minimizing the chances of 
records identification (Dwork et al. 2006; Dwork et al. 2008; Duchi et al. 2013;). 
The mechanisms of achieving DP mainly includes adding Laplace noise 
(Dwork et al. 2006; Chaudhuri and Monteleoni 2009), generating noisy 
histogram and synthetic data, (Lei 2011), and functional perturbation (Zhang 
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2012). DP has strong theoretical foundation and is a well-recognized approach 
in the privacy-preserving research society. If our objective were to build one 
model for all patients (i.e., adopting the one-model-fits-all approach), DP would 
be an appropriate approach by providing theoretical guarantee that not a single 
patient’s information is identifiable. However, patients are highly 
heterogeneous and each patient needs a different model. This unique property 
of our application makes DP unsuitable. Another category of privacy-
preserving techniques is cryptography. For example, homomorphic encryption 
(Paillier 1999; Gentry 2009) enables other parties to perform computation on 
the data without possession of the private key. Emam et al. (2012) proposed a 
regression framework with the Paillier cryptosystem using a number of secure 
building blocks. Cryptography is not suitable for our application due to the same 
reason mentioned above for DP. Additionally, the encryption steps may 
potentially prolong the time for model building/training and model 
utilization/deployment, which results in negative user experience. In summary, 
privacy preserving is not discussed in the existing transfer learning literature 
and transfer learning is not studied in the privacy preserving research society. 
There is a missing link between the two areas/societies.  
• Lack of approach for preventing negative transfer: Negative transfer refers 
to the situation when transfer learning from a source domain results in a worse 
model for the target domain than that without transfer learning. Although 
negative transfer has been recognized as an important issue in transfer learning, 
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only a few papers have embraced an explicit consideration to guard against 
negative transfer. Seah et al. (2016) proposed a predictive distribution matching 
(PDM) regularizer to identify and remove irrelevant source samples. Gong et 
al. (2012) proposed a Rank of Domain (ROD) metric to rank source domains 
in terms of how suitable they are for helping model the target domain. Duan et 
al. (2012) proposed a Domain Selection Machine (DSM) for selecting source 
domains to be used to help prediction on the target domain. Ge et al. (2014) 
proposed a two-phase transfer learning framework to prevent negative transfer, 
which first assigned Supervised Local Weight (SLW) to each source domain 
and then built a Reproducing Kernel Hilbert Space (RKHS) classifier for the 
target domain that balanced the prediction error on labeled data and consistency 
with weighted predictions from source domains on unlabeled data. The 
aforementioned existing work has limitations: The methods proposed by Gong 
et al. (2012) and Seah et al. (2013) fall into the categories of instance and 
feature transfer, respectively, which do not offer the privacy-preserving 
capability. The method by Duan et al. (2012) is conceptually more similar to 
ensemble learning than transfer learning. The method by Ge et al. (2014) was 
built on the RKHS space, and therefore it cannot explicitly show the predictor-
response relationship to facilitate predictor selection and model interpretation. 
A white-box model is more preferred to facilitate understanding by clinicians 
and consequently would have better acceptance in health care applications. 
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1.3 Expected Original Contribution 
The objective of my research is to develop new transfer learning methods that 
overcome the aforementioned limitations of the existing methods and demonstrate their 
utility in sub-areas of health care application, including telemonitoring and radiomics for 
glioblastoma. The expected original contributions include: 
• Development of a mixed effects transfer learning (METL) model: I develop 
a METL model that can flexibly incorporate mixed effects and a general-form 
covariance matrix to better account for similarity and heterogeneity across 
subjects. I further develop computationally efficient procedures to handle 
unknown parameters and large covariance structures. Domain relations such as 
domain similarity and domain covariance structure are automatically quantified 
in the estimation steps. I demonstrate METL in an application of smartphone-
based telemonitoring of the Parkinson’s Disease (PD). The details of this work 
are illustrated in chapter 2. 
• Development of transfer learning model for radiomics of glioblastoma: I 
develop an MRI-based transfer learning algorithm for non-invasive surgical 
guidance of GBM patients. Limited biopsy samples per patient create a 
challenge to build a patient-specific model for GBM. A transfer learning 
framework helps to leverage knowledge from other patient’s knowledge for 
building a better predictive model. When modeling a target patient, not every 
patient’s information is helpful. Deciding the subset of other patients from 
which to transfer information to the modeling of the target patient is an 
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important task to build an accurate predictive model. I define the subset of 
“transferrable” patients as those who have a positive rCBV-cell density 
correlation, because a positive correlation is confirmed by imaging theory and 
the literature. The proposed transfer learning model especially shows 
particularly high predictive performance for the non-enhancing tumor segment 
that is problematic to the diagnosis and treatment of GBM. The details of this 
work are illustrated in chapter 3. 
• Development of a privacy-preserving positive transfer learning (P3TL) 
model: In my radiomics work described previously, I preliminarily explored 
the issue of negative transfer by identifying a subset of transferrable patients to 
a target patient based on imaging theory and medical domain knowledge. In this 
work, I would like to perform an in-depth theoretical investigation on the issue 
of negative transfer, coupled with consideration of privacy-preserving, to 
develop a new algorithm called P3TL. Specifically, I perform a theoretical 
study by deriving the generalization bound of a previously developed transfer 
learning model called Bayesian Parameter Transfer (BPT), by Na et al. (2015), 
which reveals that the risk of negative transfer exists in BPT. After confirming 
the existence, I perform further theoretical study to investigate the key element 
in BPT that causes negative transfer and identify a sufficient and necessary 
condition for negative transfer to happen. This points out the direction where 
P3TL can make improvement. Note that although negative transfer has been 
recognized as an important issue by the transfer learning research community, 
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there is a lack of theoretical studies in evaluating the risk of negative transfer 
for a transfer learning method and identifying what causes the negative transfer. 
My work fills this gap. Driven by the theoretical insights, I extend BPT to a 
new method, i.e., P3TL, which is robust to negative transfer and is privacy-
preserving. These features make P3TL an excellent model for telemonitoring. 
The details of this work are illustrated in chapter 4. 
 
1.4 Dissertation Organization 
My dissertation research will be presented in three chapters, as shown in Figure 1. 
Chapter 2 presents the development of topic (I): mixed effects transfer learning model for 
smartphone-based telemonitoring. Chapter 3 presents the development of topic (II): 
accurate Patient-specific Machine Learning Models of Glioblastoma Invasion using 
Transfer Learning. Chapter 4 presents the development of topic (III): Privacy-Preserving 
Positive Transfer Learning (P3TL) Approach for Telemonitoring of Parkinson’s Disease. 
Chapter 5 summarizes the dissertation with conclusion remarks and discussions on future 
work. 
 









Approximately 77% of Americans own a smartphone, according to the newest year 
2018 statistics from the Pew Research Center surveys. Smartphones hold a wealth of 
information regarding people’s daily activities. The information ranges from sensor 
observations (e.g., captured by accelerometer, gyroscopes, compass, camera, and 
microphone) to textual observations (e.g., social media updates and SMS). With the 
abundant information, there is a growing trend of using smartphones to improve health care 
through various types of mobile health technology such as mobile health apps, mobile-
enabled patient portals, and telemedicine. For example, heart rate, oxygen saturation, and 
stress level can be collected through built-in camera (Garcia-Ceja et al. 2016). Cardiac 
measurements can be collected through built-in sensors when patients place their devices 
on the skin near the heart (Lee et al. 2018). A specialized app can capture blood-glucose 
information and transmit it to the doctor in real-time for management of diabetes (Newman 
et al. 2005) 
Particularly, recent years have witnessed the use of smartphones for remotely 
monitoring (i.e., telemonitoring) the Parkinson’s Disease (PD). PD is the second most 
common neurodegenerative disorder and currently affects around seven to ten million 
people worldwide. PD symptoms include tremor, slowed movement, rigid muscles, 
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impaired posture and balance, loss of automatic movements, and speech changes, which 
greatly affect patients’ quality of life. There is no known cure for PD, but treatments can 
help control and mitigate the effect of these symptoms. For effective treatment, doctors 
need to frequently assess patients’ disease development and status so that treatment can be 
adjusted timely to keep up with the disease progression. Conventionally, this has to be done 
in a specialized clinic with the patient’s physical presence, which is costly and logistically 
inconvenient for both the patient and medical staff. As a result, insufficient clinical 
examinations are not uncommon, which lead to sub-optimal treatment as the treatment 
always lags behind the progressing disease. To improve this situation, smartphones have 
emerged to become a new platform to allow for frequent, cost-effective, and logistically-
convenient telemonitoring of PD related symptoms.  
Among the existing efforts on smartphone-based telemonitoring of PD, Sage 
Bionetworks developed a specialized app, mPower, which collects pre-designed activities 
like tapping, walking, memorizing, and speaking that measure PD symptoms with minimal 
or no interruption in the participant’s daily life. Collected activity information can be 
transformed to useful features for better understanding of the disease progression. These 
activities can be performed at home. This logistic convenience and cost-effectiveness allow 
patient conditions to be assessed frequently and treatment plans to be adjusted timely to 
achieve the optimal effect.  
Mobile apps for PD are typically paired up with predictive analytics that “translates” 
the monitored symptomatic signals into a clinical indicator of the disease severity. For 
quantifying PD severity, a most commonly used instrument is the Unified Parkinson's 
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disease rating scale (UPDRS), which is a survey consisting of 42 questions given to patients 
to check PD related symptoms. The summary score of the answers to the 42 questions, 
known as the UPDRS score, is used as a clinical indicator of PD severity. Therefore, it is 
an important task to build a predictive model that uses smartphone-collected telemonitoring 
signals to predict the UPDRS score for each patient, which allow for optimal medical 
treatment for the right person at the right time.   
However, this predictive modeling is not straightforward because of the following 
challenges: first, just like many other fields of medicine, patient heterogeneity must be 
accounted for, which is indeed the driving force for the current paradigm shift of health 
care toward personalized or precision medicine. In the context of telemonitoring, patient 
heterogeneity means that each patient may have a different relationship between the 
telemonitoring signals and disease severity, and thereby a different predictive model. 
Building a separate model for each patient suffers from small sample sizes. A small sample 
size in the training dataset is common in telemonitoring applications because there is a 
need to train a model timely (i.e., using a small number of repeated measurements on the 
disease severity), so that the model can be deployed to use the telemonitored activity data 
to predict patient disease severity and progression without the patient’s physical presence 
at the clinic. Transfer learning provides a better model than separate modeling of each 
patient, which builds models for multiple related tasks (e.g., PD patients) to allow the 
models to borrow strength from each other and compensate for sample shortage within 
each task. However, existing transfer learning methods fall short for satisfying the need of 
predictive modeling in telemonitoring because they do not account for the within-patient 
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correlation of samples that are repeated measurements of disease severity. Predictive 
models that do not reply on sample independence assumption and can account for 
complicated correlation structure belong to a special category of mixed effects models 
(MEM). Existing MEM models can be used to build a separate model for each patient but 
not capable of building joint models across different patients (i.e., the concept of TL). To 
our best knowledge, there is no existing method that integrates MEM and TL in a single 
framework.  
To address the aforementioned challenges, we propose a Mixed Effects Transfer 
Learning (METL) model that uses a general-form covariance matrix to better account for 
similarity and heterogeneity across subjects. To the best of our knowledge, such a model 
is not available in the existing literature.  
The rest of this article is organized as follows: Section 2.2 reviews the existing 
research and points out the limitations. Section 2.3 briefly introduces the Linear Mixed 
Models (LMM) and presents the development of METL including mathematical 
formulation, the estimation algorithm with proof of convergence. Section 2.4 presents 
simulation studies, Section 2.5 presents a real-data application of using METL to predict 
UPDRS of PD patients with their smartphone-collected activity signals. The dataset for 
this application is collected by the mPower study.  
 
2.2 Literature Review 
This work intersects with two fields: transfer learning and linear mixed models. The 
overview of TL models are described in Chapter 1. Therefore, we only include literature 
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review of linear mixed models. 
Linear Mixed Models (LMM). LMM is a class of statistical models that relax the 
independence assumption of observations/samples by including random effects in the 
models. This allows for modeling more complicated data structures. LMM is particularly 
useful when the data is taken as repeated measurements for each subject so that there is 
natural correlation within the measurements. This is the case for the training dataset of 
telemonitoring, which consists of repeated measurements of a disease severity variable for 
each patient to track the progression. LMM is a sub-class of the general mixed effects 
models (MEM), which assumes a linear relationship between the response and predictors. 
Other variants of MEM include nonlinear MEM using kernel functions to characterize the 
nonlinear relationship between the predictor vector and a parameter vector (Lindstrom and 
Bates 1990; Davidian and Giltinan 2003), but these approaches still assume that individuals 
are drawn from a population and share common features. Another variant of MEM is 
generalized LMM(GLMMs) that incorporates random effects and generalized linear 
models for analyzing non-Gaussian responses such as binary or counts, or proportions by 
using link functions and exponential family distributions (Bolker et al. 2009; McCulloch 
and Neuhaus 2014); Variants of MEM also include semi-parametric MEM that uses a 
nonparametric function to model a time-varying effect and a parametric function to model 
other covariate effects to account for the within subject correlation (Li et al. 2010). 
Additionally, another variant of MEM is generalized additive MEM that uses a nonlinear 
smooth function to capture relationship between individual predictors and dependent 
variable by treating random effects as smooths (Fahrmeir and Lang 2001; Wood 2006). 
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Variants of MEM also include generalized varying coefficient MEM that accounts for not 
only current observations of the predictor but also recent values of the predictor process 
that affect current response. (Şentürk and Müller 2008). 
Specific to what the present paper concerns, i.e., building an accurate model to 
predict disease severity using smartphone-collected telemonitoring signals, we need a 
MEM model such as an LMM to account for within-patient correlation between the 
repeated disease severity measurement. Meanwhile, we also need an TL model because all 
the patients have the same disease. Although inter-patient heterogeneity exists, which 
prevents pooling all patients’ data together to build one model that fits all, we should use 
TL to build patient-specific models jointly rather than separately in order to leverage their 
relatedness to improve the generalization performance of the models, especially 
considering that each patient only has very limited samples. However, to our best 
knowledge, no model exists to integrate LMM and TL in a single framework, which 
motivates the development of the propose METL model in this chapter. In what follows, 
we will first introduce the conventional LMM (Section 2.3.1), and then present the 
development of METL by incorporating TL into LMM (Section 2.3.2).  
 
2.3 Development of the Proposed METL Model 
2.3.1 Introduction to linear mixed model (LMM) 
We present the existing LMM in this section. In the next section, we present the 
development of the proposed METL as extension of the LMM. Suppose there are 𝐾 
subjects. For each subject 𝑖 , 𝑖 = 1,… , 𝐾 , there are 𝑛𝑖  observations. Let 𝐲𝑖  contain 𝑛𝑖 
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measurements for a response variable of interest, e.g., the UPDRS score of the 𝑖-th patient. 
Let 𝑿𝑖  be the 𝑛𝑖 × 𝑝 design matrix for 𝑝 predictors. For example, the predictors can be 
features extracted from smartphone-collected symptomatic signals as well as covariates 
such as patient gender, age, and other variables that could potentially affect UPDRS. A 
linear regression model that links 𝐲𝑖 and 𝑿𝑖 would not be appropriate because 𝐲𝑖 consists 
of repeated measurements for the UPDRS score of the patient, which are not independent 
of each other. This violates the I.I.D. assumption of a linear regression model. LMM 
provides a more appropriate model to account for the inter-measurement dependence, 
which takes the following form:  
𝐲𝑖 = 𝐗𝑖𝛃 + 𝐙𝑖𝐛𝑖 + 𝜺𝑖 . 
Here, the linear coefficients in 𝛃 are called fixed effects whereas 𝐛𝑖 is a 𝑞 × 1 vector of 
subject-specific random effects. 𝐛𝑖~𝑁𝑞(𝟎, 𝐆) . 𝒁𝑖  is an 𝑛𝑖 × 𝑞  design matrix 
corresponding to the random effects. 𝒁𝑖  contains features extracted from smartphone-
collected symptomatic signals. 𝜺𝑖 is a 𝑛𝑖 × 1 vector of the errors, 𝜺𝑖~𝑁(0, 𝐑𝑖).  
 
2.3.2 Mathematical formulation of METL 
In the existing LMM described in the previous section, the random effects for 𝑖-th 
subject are assumed to follow a multivariate zero-mean normal distribution with covariance 
matrix 𝐆, i.e., 𝐛𝑖~𝑁𝑞(𝟎, 𝐆). This assumption has two limitations: 1) the same 𝐆 is assumed 
for all the subjects, without considering subject heterogeneity; 2) subjects are modeled 
independently, i.e., 𝐛𝑖 and 𝐛𝑗 are assumed to be independent, without considering potential 
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subject similarity. To overcome these limitations and better account for subject 
heterogeneity and similarity, we propose to use a matrix-normal distribution for the pooled 
random effects across all the subjects. Specifically, we pool the subject-wise random effect 
vectors into a matrix, 𝐁 = (𝐛1, … , 𝐛𝑖, … , 𝐛𝐾). 𝐁 is assumed to follow a zero-mean matrix-
normal distribution, i.e., 𝐁~𝑀𝑁(𝟎, 𝐆,𝛀).  𝐆 ∈ ℝ𝑞×𝑞 is the row-wise covariance matrix 
that characterizes the covariances between the 𝑞 random effects. 𝛀 ∈ ℝ𝐾×𝐾 is the column-
wise covariance matrix that characterizes the covariances between subjects. Next, we show 
the benefits of METL in comparison with LMM in a more explicit way:  
• In LMM, 𝑐𝑜𝑣(𝐛𝑖) = 𝐆  for all subjects.  In METL, 𝑐𝑜𝑣(𝐛𝑖) = 𝛀𝑖𝑖𝐆 for the i-th 
subject, where 𝛀𝑖𝑖  is the 𝑖 -th diagonal element of 𝛀 . This means that the 
covariance matrix between random effects is allowed to vary across different 
subjects. 
• Let 𝐛𝑗 be the 𝑗-th row of 𝐁, which contains random effects corresponding to the 
𝑗-th predictor across all the subjects. In LMM, 𝑐𝑜𝑣(𝐛𝑗) = 𝐈  for all predictors. In 
METL, 𝑐𝑜𝑣(𝐛𝑗) = 𝐆𝑗𝑗𝛀 for the j-th predictor. This means that the subjects are 
allowed to be correlated in their random effects corresponding to the same 
predictor.  
Finally, we write the mathematical formulation of METL as follows: 
              𝐲𝑖 = 𝐗𝑖𝛃 + 𝐙𝑖𝐛𝑖 + 𝜺𝑖  , 𝐁~𝑀𝑁(𝟎, 𝐆,𝛀), 𝜺𝑖~𝑁(0, 𝐑), 𝑖 = 1,… , 𝐾.               (2.1) 
To estimate all the unknown parameters of the METL is not straightforward, as it involves 
mathematical derivations to identify explicit functional forms, solving of optimization 
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problems, and strategies to improve computational efficiency and numerical stability. In 
the next section, we will present the development of estimation algorithms for METL.  
 
2.3.3 Estimation algorithm for METL 
The proposed METL in (2.1) involves unobserved variables, 𝐛𝑖, 𝑖 = 1,… , 𝐾, which 
make it difficult for a direct estimation of the model parameters using Maximum 
Likelihood Estimation (MLE).  Expectation-Maximization (EM) is a general method for 
finding the maximum likelihood estimates of model parameters from data with missing 
values (Dempster et al., 1977). EM works by iteratively conducting two steps: The E-step 
is to find the expectation of the complete-data log-likelihood with respect to the 
unobserved/missing data given the observed data and the current parameter estimates. The 
M-step is to find parameter estimates that maximize the expectation in the E-step. The two 
steps are repeated until convergence. The EM framework has the desirable property that it 
is guaranteed to converge to a local maximum of the likelihood function (Wu, 1983). The 
challenge of using the general EM framework for parameter estimation of a specific model 
includes finding the expectation in the E step and solving the optimization in the M step. 
These steps are not trivial for our proposed METL model. In what follows, we present the 
derivations in the E and M steps for METL:  
For the convenience of subsequent discussion, we stack up the subject-specific 
model in (2.1) into the following:  




























































𝐲 follows a normal distribution with mean 𝐗𝛃 and covariance matrix 𝐕 = 𝐙(𝛀⨂𝐆)𝐙𝑻 +
𝐑. ⨂ denotes the Kronecker product of two matrices. Let 𝑁 = ∑ 𝑛𝑖
𝐾
𝑖=1 . We put all the 
parameters to be estimated for the METL in (2.2) into a set, i.e., 𝝓 = (𝛃, 𝐆,𝛀, 𝐑). The log-
likelihood function of the parameter set 𝝓, after dropping constants, can be obtained as: 






[(𝐲 − 𝐗𝛃)𝑇𝐕−1(𝐲 − 𝐗𝛃)]                    (2.3) 
Furthermore, by treating the random effects in 𝐛 as observed data and dropping constants, 
we can write the complete-data log-likelihood function as 






[(𝐲 − 𝐗𝛃 − 𝐙𝐛)𝑇𝐑−1(𝐲 − 𝐗𝛃 − 𝐙𝐛)] 









𝑡𝑟 (𝐛𝑇(𝛀⨂𝐆)−1𝐛)                                                     (2.4) 
 
2.3.3.1 Perform the E-step  
In the 𝜔-th iteration of the E-step, our goal is to compute the expectation of the 
criterion in equation (2.4) with respect to the conditional distribution of 𝐛 given 𝐲 and the 
current estimate of 𝝓, 𝝓(𝜔). For simplicity of the presentation, we use 𝝓 instead of 𝝓(𝜔) 
in the remaining discussion of this section. It can be derived that the conditional distribution 
of 𝐛|𝐲,𝝓 is normal with mean and covariance as: 
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𝐸(𝐛|𝐲,𝝓) = (𝛀⨂𝐆)𝐙𝑇(𝐙(𝛀⨂𝐆)𝐙𝑇 + 𝐑)−1(𝐲 − 𝐗𝛃),                                                                 (2.5) 
𝑐𝑜𝑣(𝐛|𝐲, 𝝓) = (𝛀⨂𝐆) − (𝛀⨂𝐆)𝐙𝑇(𝐙(𝛀⨂𝐆)𝐙𝑇 + 𝐑)−1𝐙(𝛀⨂𝐆)                                       (2.6) 
However, to obtain the numerical values for (2.5) and (2.6) at each E-step iteration is 
difficult because of the need for inverting a large matrix, 𝐙(𝛀⨂𝐆)𝐙𝑇 + 𝐑, which has a 
dimension of 𝑁 × 𝑁. Recall that each subject has 𝑛𝑖  observations and 𝑁 is the sum of 
observations from all the subjects. In the real-data case study presented in Section 2.4.3, 
𝑁 =  1600. Inverting a matrix of such large dimension is neither computationally efficient 
nor numerically stable.  
To tackle this difficulty, we propose equivalent formats for (2.5) and (2.6) in 
Proposition 1. The new formats achieve computational efficiency and numerical stability 
by two means: First, they only require inversion of a much smaller matrix, i.e., 𝐙𝑇𝐑−1𝐙 +
(𝛀⨂𝐆)−1, which has a dimension 𝑞 × 𝐾 by 𝑞 × 𝐾. Recall that 𝑞 is the number of random 
effects and 𝐾 is the number of subjects. In the case study in Section 2.4.3, 𝑞 × 𝐾 is only 
200. Furthermore, because 𝛀⨂𝐆 is positive definite by nature, it can be written as 𝛀⨂𝐆 =
𝚪𝛀⨂𝐆𝚪𝛀⨂𝐆
𝑇  by the Cholesky decomposition, where 𝚪𝛀⨂𝐆 is a lower triangular matrix. As a 




−1 . This further simplifies the need for inverting 𝛀⨂𝐆 by 
only needing to invert a lower triangular matrix 𝚪𝛀⨂𝐆 which is a much easier operation.  
 
Proposition 2.1: Let 𝚪𝛀⨂𝐆 be the lower triangular matrix in the Cholesky decomposition 
of 𝛀⨂𝐆, i.e., 𝛀⨂𝐆 = 𝚪𝛀⨂𝐆𝚪𝛀⨂𝐆








−1 )−1𝐙𝑇𝐑−1(𝐲 − 𝐗𝛃),              (2.7) 




−1 )−1.                            (2.8) 
 
Proof:  Multiplying 𝐙𝑇𝐑−1 to (𝐙(𝛀⨂𝐆)𝐙𝑇 + 𝐑), we get 
𝐙𝑇𝐑−1(𝐙(𝛀⨂𝐆)𝐙𝑇 + 𝐑)= (𝐙𝑇𝐑−1𝐙 + (𝛀⨂𝐆)−1)(𝛀⨂𝐆)𝐙𝑇.                                       (2.9) 
Furthermore, multiplying (𝐙𝑇𝐑−1𝐙 + (𝛀⨂𝐆)−1)−1 to the left and (𝐙(𝛀⨂𝐆)𝐙𝑇 + 𝐑)−1 
to the right for both sides in (2.9), we get 
(𝐙𝑇𝐑−1𝐙 + (𝛀⨂𝐆)−1)−1𝐙𝑇𝐑−1 = (𝛀⨂𝐆)𝐙𝑇(𝐙(𝛀⨂𝐆)𝐙𝑇 + 𝐑)−1.                          (2.10) 
Then, insert the left-hand side of (2.10) into (2.7) and (2. 8), we get 
𝐸(𝐛|𝐲,𝝓) = (𝐙𝑇𝐑−1𝐙 + (𝛀⨂𝐆)−1)−1𝐙𝑇𝐑−1(𝐲 − 𝐗𝛃),          (2.11) 
𝑐𝑜𝑣(𝐛|𝐲, 𝝓) = (𝛀⨂𝐆) − (𝐙𝑇𝐑−1𝐙 + (𝛀⨂𝐆)−1)−1𝐙𝑇𝐑−1𝐙(𝛀⨂𝐆)    
= (𝛀⨂𝐆) − (𝐙𝑇𝐑−1𝐙 + (𝛀⨂𝐆)−1)−1(𝐙𝑇𝐑−1𝐙 + (𝛀⨂𝐆)−1 − (𝛀⨂𝐆)−1)(𝛀⨂𝐆) 
= (𝛀⨂𝐆) − (𝐙𝑇𝐑−1𝐙 + (𝛀⨂𝐆)−1)−1(𝐙𝑇𝐑−1𝐙 + (𝛀⨂𝐆)−1)(𝛀⨂𝐆)
+ (𝐙𝑇𝐑−1𝐙 + (𝛀⨂𝐆)−1)−1(𝛀⨂𝐆)−1(𝛀⨂𝐆) 
= (𝐙𝑇𝐑−1𝐙 + (𝛀⨂𝐆)−1)−1.            (2.12) 
Finally, inserting 𝛀⨂𝐆 = 𝚪𝛀⨂𝐆𝚪𝛀⨂𝐆
𝑇  into (2.11) and (2.12), we can get (2.7) and (2.8), 
i.e.,  




−1 )−1𝐙𝑇𝐑−1(𝐲 − 𝐗𝛃),  




−1 )−1.   ∆ 
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2.3.3.2 Perform the M-step  
In the M-step, our goal is to maximize Q(𝝓|𝝓(𝜔)) with respect to 𝝓 at the 𝝎th 
iteration.  








𝐸[(𝐲 − 𝐗𝛃 − 𝐙𝐛)𝑇𝐑−1(𝐲 − 𝐗𝛃 − 𝐙𝐛)|𝒚,𝝓(𝜔)] 









𝑡𝑟𝐸(𝐁𝑇𝐆−1𝐁𝛀−1|𝐲,𝝓(𝜔))                                      (2.14) 
It is difficult to optimize the parameters in 𝝓 all at once. We choose to alternate between 
optimizations of subsets of the parameters in 𝝓  to achieve a faster converging rate. 
Specifically, split 𝝓 into two subsets, (𝐆,𝛀) and (𝛃, 𝐑). When optimizing the parameters 
contained in each subset, those in other subsets are assumed fixed. Next, we will present 
the details for solving each sub-optimization problem:  
 
1) Solving for (𝐆,𝛀) given 𝛃 and 𝐑 












𝑡𝑟𝐸(𝐁𝑇𝐆−1𝐁𝛀−1|𝐲,𝝓(𝜔))                    (2.15) 
(2.15) is not a convex optimization with respect to (𝐆,𝛀). On the other hand, given one 
parameter (𝐆 or 𝛀), the optimization with respect to the other parameter is convex and can 











Taking the derivative of Q𝛀(𝛀|𝝓
(𝜔), 𝐆∗) with respect to 𝛀 and equalizing the derivative 
to be zero, we can the optimal solution for 𝛀 as: 
   ?̂? =
1
𝑞
𝐸(𝐁𝑇𝐆∗−1𝐁|𝐲,𝝓(𝜔)),                                            (2.16) 
In a similar manner, we can get the optimal solution for 𝐆 given 𝛀∗ as: 
   ?̂? =
1
𝐾
𝐸(𝐁𝛀∗−1𝐁𝑇|𝐲, 𝝓(𝜔)).                        (2.17) 
(2.16) and (2.17) will be performed iteratively until convergence.  
Furthermore, we discuss how to obtain the explicit forms of the expectations in 
(2.16) and (2.17) as follows: 𝐁𝑇𝐆∗−1𝐁 in (2.16) is a 𝐾 × 𝐾 matrix. We can derive the 

















(𝜔))  is the sub-vector of (2.7) corresponding to the 𝑖 -th subject; 
𝑐𝑜𝑣(𝐛𝑖, 𝐛𝑗|𝐲, 𝝓
(𝜔)) is a submatrix of (2.8) corresponding to the 𝑖-th and 𝑗-th subjects.  
In the similar manner, the expectation of 𝐁𝛀∗−1𝐁𝑇  in (2.17) can be computed 
element-by-element. Let 𝐛𝑖 denote the 𝑖-th row of 𝐁. We can derive the expected value for 














∗ −1𝑐𝑜𝑣(𝐛𝑖, 𝐛𝑗|𝐲,𝝓(𝜔))),  
where 𝐸(𝐛𝑖|𝐲, 𝝓(𝜔)) is the sub-vector of (2.7) corresponding to the 𝑖-th random effect 
predictor; 𝑐𝑜𝑣(𝐛𝑖 , 𝐛𝑗|𝐲,𝝓(𝜔)) is a submatrix of (2.8) corresponding to the 𝑖-th and 𝑗-th 
random effect predictors.  
 
2) Solving for 𝛃 and 𝐑 given (𝐆,𝛀) 
By treating (𝐆,𝛀) and 𝐑 as constants and 𝛃 as the unknown, (2.14) can be written 
as: 




𝐸[(𝐲 − 𝐗𝛃 − 𝐙𝐛)𝑇𝐑−1(𝐲 − 𝐗𝛃 − 𝐙𝐛)|𝒚,𝝓(𝜔)],  (2.18) 
which has a close-form solution, i.e.,  
                  ?̂? = (𝐗𝑇𝐑−1𝐗)−1𝐗𝑇𝐑−1(𝐲 − 𝐙𝐸(𝐛|𝐲,𝝓(𝜔))),                 (2.19) 
where the explicit form of 𝐸(𝐛|𝐲,𝝓(𝜔)) is given in (2.7). 









𝐸[(𝐲 − 𝐗𝛃 − 𝐙𝐛)𝑇𝐑−1(𝐲 − 𝐗𝛃 − 𝐙𝐛)|𝒚,𝝓(𝜔)]          (2.20) 
Without loss of generality, assume 𝐑 = 𝜎𝑒
2𝐈𝑁. The optimization of (24) with respect to 𝜎𝑒
2 











[(𝐲 − 𝐗?̂? − 𝐙𝐸(𝐛|𝐲,𝝓(𝜔)))
𝑇
(𝐲 − 𝐗?̂? − 𝐙𝐸(𝐛|𝐲,𝝓(𝜔))) +
𝑡𝑟 (𝐙𝑇𝐙𝑐𝑜𝑣(𝐛|𝐲,𝝓(𝜔)))],           (2.21) 
where the explicit forms of 𝐸(𝐛|𝐲,𝝓(𝜔)) and 𝑐𝑜𝑣(𝐛|𝐲,𝝓(𝜔)) are given in (2.7) and (2.8).  
Finally, we summarize the major steps and iterations of the algorithm for parameter 
estimation of METL in Algorithm 2.1: 
 
Algorithm 2.1 METL 
Input: Design matrices for K patients, {𝐗𝑖, 𝐙𝑖}𝑖=1
𝐾 , data of response variable, {𝒚𝑖}𝑖=1
𝐾 ;  
Initialize: 𝝓(0) = (𝛃(0), 𝐆(0), 𝛀(0) , 𝜎𝑒
2(0)) . set the iteration number,  𝜔 ← 0 
Iterate until convergence: 
     E-step: Calculate 𝐸(𝐛|𝐲,𝝓(𝜔)) and 𝑐𝑜𝑣(𝐛|𝐲, 𝝓(𝜔)) using (2.7) and (2.8),    
                  respectively. 
     M-step: 𝐆(ω+1), 𝛀(ω+1), 𝛃(𝜔+1), 𝜎𝑒
2(𝜔+1)  
          (1) Identify covariance relationships. Solve for (𝐆,𝛀) analytically given  𝛃(𝜔)    
                and 𝜎𝑒
2(𝜔).      
               Alternate between following two sub-steps to get 𝐆(ω+1) and 𝛀(ω+1) 
               Set the alternation number,  ψ ← 0    
                    i) Compute (𝐆(ω+1))[ψ+1] by using equation (2.16) given (𝛀(ω+1))[ψ] 
ii) Compute(𝛀(ω+1))[ψ+1] by using equation (2.17) given (𝐆(ω+1))[ψ+1] 
   Increase alternation number by 1, ψ ← ψ + 1.   
          (2) Alternate between following two sub-steps to get 𝛃(𝜔+1) and 𝜎𝑒
2(𝜔+1)  
                Set the alternation number,  ψ ← 0   
                    i) Compute (𝛃(ω+1))[ψ+1] by using equation (2.19) given (𝜎𝑒
2(𝜔+1))[ψ]  
ii) Compute 𝜎𝑒
2(𝜔+1) by using equation (2.21) given (𝛃(ω+1))[ψ+1] 
               Increase alternation number by 1, ψ ← ψ + 1.   
           Increase iteration number by 1, ω ← ω+ 1. 






2.3.4 Convergence of the Algorithm 
In this study, convergence is a consequence of the iterative algorithm used to solve for  
𝝓 = (𝛃,𝐆,𝛀,𝐑) in E and M steps and alternating within two sub-steps in the M-step to get  
𝐆(𝜔+1), 𝛀(𝜔+1), 𝛃(𝜔+1)𝑹(𝜔+1).  The EM framework has the desirable property that it is 
guaranteed to converge at a local maximum of the likelihood function (Wu, 1983). Liu and 
Rubin (1994) show that the EM algorithm monotonically increases the likelihood function. 
In the M-step of the proposed algorithm, we have two alternating sub-steps for 1) 𝛀 and 𝐆, 
and 2) 𝛃 and 𝐑. Therefore, the key to prove the convergence of the METL is to show the 
convergence of two sub-steps in the M-step. According to Tseng (2001), the Block 
Coordinate Descent (BCD) algorithm is guaranteed to converge at the optimal solution if 
the term is transformed into convex optimization form through separation. We will apply 
the BCD algorithm to each sub-step in the M-step. Next, we will present the details of 
convergence in each sub-step.  
 
1) Convergence of (𝐆,𝛀) 
Specifically, given 𝐆, then 𝐐(𝛀|𝝓(𝜔), 𝐆(𝜔)) becomes a convex optimization with respect 
to 𝛀, which can be solved efficiently. In the same manner, given 𝛀, the optimization 
problem 𝐐(𝐆|𝝓(𝜔), 𝛀(𝜔))  with respect to 𝐆  can be solved analytically. The iteration 
between two sub-optimizations can solve for 𝐆 and 𝛀.  
The M-step 1 consists of the reduced optimization problem as (2.15). Specifically, 
given 𝐆∗, the optimization becomes: 
Q𝛀(𝛀|𝝓






𝑡𝑟 𝐸(𝐁𝑇𝐆∗−1𝐁𝛀−1|𝐲,𝝓(𝜔)).                 (2.22) 
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The BCD algorithm converges if and only if the problem has a unique solution for each 
iteration. The unique solution is guaranteed if the equation (2.22) is strictly convex. The 
strictly convexity is true if 𝛀 is positive definite in (2.22). Because the BCD algorithm 
works by iterations of all K tasks for 𝛀, we will only demonstrate steps performed in a 
single iteration since all other iterations work in a similar way.  
Let 𝛀\𝐾\𝐾  be the matrix produced by removing row K and column K from 𝛀,  
ω𝐾𝐾 be the element at row K and column K of 𝛀, and 𝛀𝐾 be the column K of 𝛀 with 










Expanding the block matrix multiplication within the trace in (2.22) and simplifying the 

















































(𝜔))                      (2.23) 
By taking the partial derivative of (2.22) with respect to ω𝐾𝐾 and making the partial 






























(𝜔))         
(2.24) 
Since 𝐆(𝜔) in equation (2.24) is positive definite and a positive definite matrix has 
property, 𝑣𝑇𝐆(𝜔)𝑣 > 0 𝑎𝑙𝑙 𝜐 ∈ ℝ𝑛, then we know the following inequality, 
                                             ω𝐾𝐾 − 𝛀𝐾
𝑇𝛀\𝐾\𝐾
−1 𝛀𝐾 > 0.                        (2.25) 
By mathematical induction with a basis and inductive step, we can prove 𝛀(𝜔+1) ≻ 0. 
Basis step: 𝛀(0) and 𝐆(0) can be defined as any initial positive definite matrix. 
Inductive step: Assuming 𝛀(𝜔) ≻ 0 and 𝐆(𝜔) ≻ 0, we need to prove 𝛀(𝜔+1) ≻ 0, which 
we can do by proving |𝛀(𝜔+1)| ≻ 0 , because there are equivalent. Since the Schur 










), we need to 
prove |𝛀\𝐾\𝐾
(𝜔)








) ≻ 0. |𝛀\𝐾\𝐾
(𝜔)
| ≻ 0 is true 
since we have assumed that 𝛀\𝐾\𝐾
(𝜔)









) ≻ 0. As a result, |𝛀(𝜔+1)| > 0 and 𝛀(𝜔+1) ≻ 0. 
When all tasks in 𝛀(𝜔+1) are updated, we can update 𝐆(𝜔+1) in a similar way. 
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Let 𝐆\𝑞\𝑞  be the matrix produced by removing row 𝑞 and column 𝑞 from 𝐆,  g𝑞𝑞 
be the element at row 𝑞 and column 𝑞 of 𝐆, and 𝐆𝑝 be the column 𝑞 of 𝐆 with g𝑞𝑞 






By using the Schur complement, |𝐆| can be decomposed as |𝐆\𝑞\𝑞||g𝑞𝑞 − 𝐆𝑞
𝑇𝐆\𝑞\𝑞
−1 𝐆𝑞|. 










































(𝜔))   (2.26) 
Since 𝛀(𝜔+1) in equation (2.26) is positive definite and a positive definite matrix has 
property, 𝑣𝑇𝛀(𝜔+1)𝑣 > 0 𝑎𝑙𝑙 𝜐 ∈ ℝ𝑛, then we know the following inequality, 
    g𝑞𝑞 − 𝐆𝑞
𝑇𝐆\𝑞\𝑞
−1 𝐆𝑞 > 0.                 (2.27) 
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By mathematical induction with a basis and inductive step, we can also prove 𝐆(𝜔+1) ≻ 0. 
The steps of mathematical induction are similar that of 𝛀 and therefore skipped. By the 
BCD algorithm, the convergence of (𝐆,𝛀) is guaranteed. 
 
2) Convergence of (𝛃, 𝐑) 
Q𝛃,𝐑(𝛃, 𝐑|𝝓
(𝜔)) is not a convex optimization with respect to unknown 𝛃 and 𝐑. If we 
consider 𝛃 and 𝐑 as two coordinates in our non-convex optimization problem, which can 
also be solved by BCD. Specifically, given 𝛃 , 𝐐(𝛀|𝝓(𝜔), 𝐑(𝜔))  becomes a convex 
optimization with respect to 𝛃, which can be solved efficiently. In the same manner, given 
𝐑 the optimization problem 𝐐(𝐑|𝝓(𝜔), 𝛃(𝜔)) with respect to 𝐑 can be solved analytically. 
Specifically, at the 𝑛-th iteration, 𝑛=1,2,3,…, BCD solves the following two optimizations 
for second-sub step in M-step: 
           (𝛃(ω+1))[ψ]  =  argmax 
𝛃 
 𝐐𝛃( 𝛀 |𝝓
(𝜔), (𝐑(ω+1))[ψ−1] )              (2.28) 
             (𝐑(ω+1))[ψ]  =  argmax 
𝐑 
 𝐐𝐑(𝐑 |𝝓
(𝜔), (𝛃(ω+1))[ψ])                  (2.29) 
(2.28) is to optimize the fixed effects coefficients, 𝛃, treating 𝐑 as fixed by using estimates 
from the previous iteration, (𝐆(ω+1))[ψ−1]. (2.29) optimizes 𝐑(ω+1)  treating fixed effects 
coefficients as fixed by using the estimate from (2.28), (𝛃(ω+1))[ψ]. Alternating (2.28) and 















|𝝓(𝜔)) ≤ 𝐐((𝛃(ω+1))[2], (𝐑(ω+1))[2]|𝝓(𝜔)) ≤ . . . ≤
𝐐((𝛃(ω+1))[ψ], (𝐑(ω+1))[ψ]|𝝓(𝜔))                                                                   (2.30) 
Remaining part of the estimation procedures (iterating between E and M-steps) holds 
convergence property of EM.  
 
2.3.5 Computational Complexity of the Algorithm 
In this study, we use the EM algorithm to solve the optimization problem. Since the 
EM algorithm consists of iteration between E and M steps until convergence, we need to 
analyze the time complexity per iteration. The definitions of 𝐾, 𝑝, 𝑞, 𝑁 are as follows, 𝐾: 
the number of tasks, 𝑝: the number of fixed effects, 𝑞: the number of random effects, 𝑁: 
the total number of samples. In the E-step, E(𝐛|𝒚,𝝓) and 𝑐𝑜𝑣(𝐛|𝒚,𝝓) are computed by 
(2.7) and (2.8). The computational complexity of the E-step is 𝑂(𝐾3𝑞3/3), which is mainly 
from inversion of 𝐾𝑞 × 𝐾𝑞 . The inversion of matrix can be optimized by Cholesky 
decomposition. Note that the computational complexity of the Cholesky decomposition of 
𝐾𝑞 × 𝐾𝑞 can be reduced as O(𝐾3𝑞3/3) Higham (2009). In the C-step, we need to compute 
the time complexity of several terms, (2.16), (2.17), (2.19), and (2.21). The time 
complexity for each term is 𝑂(𝐾2𝑞3/2 + 𝐾𝑞3/2), 𝑂(𝐾3𝑞2/2 + 𝐾3𝑞/2), 𝑂(𝑝2𝑁), and 
𝑂(𝐾3𝑞3 ). The complexity of the M-step is 𝑂(𝐾3𝑞3 ). Therefore, the computational 
complexity per iteration is 𝑂(𝐾3𝑞3). The total computational time will also be impacted 
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by the iteration numbers in EM and alternation numbers in the M-step 1 and 2. The 
proposed method converges quickly according to the simulation study in chapter 2.4. 
 
2.3.6 Theoretical Property of METL 
In this section, we will discuss the unique property of METL, a theoretical 
guarantee for larger Fisher information compared with models without transfer learning, 
which explains the outperformance of METL from a theoretical standpoint. Theorem 2.1 
shows that the better performance of METL can be attributed to a larger Fisher information. 
Because the Fisher information quantifies the variance of maximum likelihood estimators 
for the parameters of a model, a larger Fisher information indicates a smaller variance of 
the parameter estimation of model. Without loss of generality, we focus our discussion on 
the model in (2.2) with only the two tasks for the simplicity of presentation; each task 
contains only one random effect. Assume 𝜎𝟐 is fixed. METL has following form of design 
matrices and covariance matrices: 
                                              𝐲 = 𝐗𝛃 +  𝐙𝐛 + 𝛆                                               (2.2) 
     where 𝐲 = (𝐲𝑖
𝐲𝑗
), 𝐙 = (
𝐳𝑖
𝐳𝑗








                𝐛 = (𝐛𝑖
𝐛𝑗
),  𝛆 = (𝛆𝑖
𝛆𝑗
), and 𝐑 = 𝜎𝟐𝐈𝑁.  
Theorem 2.1: Let 𝐼𝑀𝐸𝑇𝐿 (𝜃𝑘𝑙)  be the Fisher information for each element in 𝐆  under 
METL. Let 𝐼𝐿𝑀𝑀 (𝜃𝑘𝑙)  be the Fisher information for each element in 𝐆  under LMM, 
respectively. Then, 
𝐼𝑀𝐸𝑇𝐿 (𝜃𝑘𝑙)  ≥ 𝐼𝐿𝑀𝑀 (𝜃𝑘𝑙)  equality holds when 𝜌𝑖𝑗 = 0 
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Under METL, the complete-data log-likelihood function is: 






[(𝐲 − 𝐗𝛃)𝑇𝐕−1(𝐲 − 𝐗𝛃)] 






𝑙𝑛|𝐈 + 𝐙𝐃𝐙𝑇| −
1
2𝜎𝟐
[(𝐲 − 𝐗𝛃)𝑇(𝐈 + 𝐙𝐃𝐙𝑇)−1(𝐲 − 𝐗𝛃)]     (2.31) 







𝐙𝑇(𝐈 + 𝐙𝐃𝐙𝑇)−1(𝐲 − 𝐗𝛃)(𝐲 − 𝐗𝛃)𝑇(𝐈 + 𝐙𝐃𝐙𝑇)−1𝐙 −
1
2
𝐙𝑇(𝐈 + 𝐙𝐃𝐙𝑇)−1𝐙 
The Fisher information is defined as the second central moment,  






let τ be 
1
𝜎
(𝐈 + 𝐙𝐃𝐙𝑇)−1/2(𝐲 − 𝐗𝛃) 
𝐼(𝜃)𝑀𝐸𝑇𝐿 = 𝑐𝑜𝑣 (𝑣𝑒𝑐ℎ ([
𝜕 𝑙(𝝓; 𝐲)
𝜕𝑫




Since the nonrandom term 
1
2
𝐙𝑇(𝐈 + 𝐙𝐃𝐙𝑇)−1𝐙 can be omitted, 𝐼(𝜃)𝑀𝐸𝑇𝐿 can be written 
as (2.32). 
𝐼(𝜃)𝑀𝐸𝑇𝐿 =  𝑐𝑜𝑣ℎ [
1
2
(𝐙𝑇(𝐈 + 𝐙𝐃𝐙𝑇)−1/2τ)(𝐙𝑇(𝐈 + 𝐙𝐃𝐙𝑇)−1/2τ)
𝑇
].                           (2.32) 
In order to derive the explicit form of (2.32), we adopt the commutation matrix and 
duplication matrix in Magnus and Neudecker (1999). The definition of commutation 
matrix 𝑲𝑛 is 𝑛
2 × 𝑛2 matrix with the property that 𝑲𝑛𝑣𝑒𝑐 𝐴 =  𝑣𝑒𝑐 𝐴
𝑇. The definition of 




𝑛(𝑛 + 1) matrix with the property. 𝑪𝑛𝑣𝑒𝑐ℎ(𝐴)  =
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Magnus and Neudecker (1999). In our case, 𝑪𝑛
+=𝑪+ is as follows, 
𝑪+ = (
1 0 0 0
0 0.5 0.5 0
0 0 0 1
) 

































                                                               (2.33) 
Since 𝐲 − 𝐗𝛃 follows normal distribution with mean 0 and covariance 𝜎𝟐(𝐈 + 𝐙𝐃𝐙𝑇)), τ 
follows 𝐍(𝟎, 𝑰𝒏) . 𝑐𝑜𝑣(𝜏⨂𝜏)  is equivalent to 2𝑁𝑛 , where 𝑁𝑛  =  (𝐼𝑛2 + 𝑲𝑛) , 𝑲𝑛  is a 
commutation matrix. The proof is found in Magnus and Neudecker (1999). Plugging 












                                                                 (2.34)   
Furthermore, utilizing one property of duplication and commutation matrices,  𝑪+𝑁𝑛 = 𝑪
+ 

















𝑪+((𝐙𝑇(𝐈 + 𝐙𝐃𝐙𝑇)−1𝐙)⨂(𝐙𝑇(𝐈 + 𝐙𝐃𝐙𝑇)−1𝐙))𝑪+
𝑇




𝑪+((((𝐙𝑇𝐙)−1 + 𝐃)−1)⨂(((𝐙𝑇𝐙)−1 + 𝐃)−1))𝑪+
𝑇
                                                   (2.35)   
Using (2.35), we can get the explicit form of Fisher information for each variance 
component under METL. The process of deriving Fisher information, 𝐼(𝜃)𝐿𝑀𝑀  under 
LMM is similar to that deriving 𝐼(𝜃)𝑀𝐸𝑇𝐿. Therefore, skipped. Here, we only present the 
results. 𝐼(𝜃𝑗𝑗) has similar form with 𝐼(𝜃𝑖𝑖).  We only include 𝐼(𝜃𝑖𝑖)  and 𝐼(𝜃𝑖𝑗)  in the 
following discussion. 




































































 .                             (2.39) 
37 
 
Subtracting the respective Fisher information of the two models, we have  








































































   



































≥ 0               (2.40) 






































































































































 ≥ 0                  (2.41) 
Equalities in (2.40) and (2.41) only holds when 𝜌𝑖𝑗 = 0.   
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Theorem 2.1 provides theoretical assurance that the covariance 𝐆, can be better estimated 
by transfer learning than single task learning in regards to a larger fisher information. (2.40) 
and (2.41) can represented following forms with respect to 𝜌𝑖𝑗, 













































                   (2.42) 
















































     (2.43) 
As the task correlation, 𝜌𝑖𝑗 , increases, 𝐼(𝜃𝑘𝑙)𝑀𝐸𝑇𝐿 − 𝐼(𝜃𝑘𝑙)𝐿𝑀𝑀  increases. Therefore, 
Theorem 2.1 shows that the more the tasks are correlated, the more knowledge can be 
transferred between tasks by METL to help reducing uncertainty of the model training of 
each task. 
 
2.4 Simulation Studies 
In this section, we use simulation data to demonstrate the performance of METL in 
comparison with the conventional LMM. The simulation data is generated as follows: fixed 
effects i.e., 𝛃 , are sampled from a 𝑁(1,  1)  distribution. Random effects, i.e., B, are 
sampled from a 𝑀𝑁(𝟎,𝐆, 𝛀)  distribution, where 𝐆𝑙ℎ = 𝜌G
|𝑙−ℎ|𝜎2 , 𝑙, ℎ = 1,… ,𝑝 , 𝜌G ∈
[−1,1] ; 𝛀𝑖𝑗 = 𝜌Ω
|𝑖-𝑗|𝜎𝑖𝜎𝑗 , 𝑖, 𝑗 = 1,… , 𝐾 , 𝜌Ω ∈ [−1,1] . Recall that 𝐆  encodes the 
covariances between the 𝑝 random effects in each task. We set 𝑝 as 10 for this simulation 
study. Making 𝐆𝑙ℎ = 𝜌G
|𝑙−ℎ|𝜎2 results in a correlation of 𝜌G
|𝑙−ℎ| between the 𝑙-th and ℎ-th 
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random effects, i.e., the random effects are allowed to have different correlations with one 
another. Also recall that 𝛀 encodes the covariances between different tasks. Making 𝛀𝑖𝑗 =
𝜌Ω
|𝑖-𝑗|𝜎𝑖𝜎𝑗 results in a correlation of 𝜌Ω
|𝑖-𝑗| between the 𝑖-th and 𝑗-th tasks, i.e., the tasks are 
allowed to have different correlations with one another. 𝛀𝑖𝑖 = 𝜎𝑖
2  reflects the variance of 
each task, which is allowed to vary across different tasks to accommodate task 
heterogeneity.  
Furthermore, we generate the data for the predictors and response variable for each 
task. Specifically, the data for the 𝑝 predictors is sampled from a multivariate normal 
distribution, i.e., 𝐗𝑖~𝑁(𝟎 , 𝚺𝑥)  for the 𝑖 -th task, where 𝚺𝑥,𝑙ℎ = 0.5
|𝑙−ℎ|  to introduce 
correlation between the predictors. Without loss of generality, 𝐙𝑖 is set to be the same as 
𝐗𝑖.  Then, data for the response variable are generated by 𝐲𝑖 = 𝐗𝑖𝛃 + 𝐙𝑖𝐛𝑖 + 𝛆𝑖, where 𝛆𝑖 
is sampled from 𝑁(𝟎,  𝐈). We consider ten predictors and one hundred samples for each 
task, respectively. 
We perform experiments to study how different factors affect the performance of 
METL in comparison with LMM, including task correlation, number of tasks, and sample 
size. The results are reported in Sections 2.4.1-2.4.3, respectively, focusing on prediction 
accuracy, and in Section 2.4.4, focusing on computational time.  
 
2.4.1 Study of the impact of task correlation on model performance 
In the aforementioned simulation setup, 𝛀  encodes the covariances between 
different tasks and we have 𝛀𝑖𝑗 = 𝜌Ω
|𝑖-𝑗|𝜎𝑖𝜎𝑗 . Under this setup, 𝜌Ω
|𝑖-𝑗| is the correlation 
between the 𝑖 -th and 𝑗 -th tasks. For the same pair of tasks, the magnitude of their 
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correlation decreases as the magnitude of  𝜌Ω  decreases. We set  𝜌Ω  ∈
 {0.1,0.3,0.5,0.7,0.9} so that we can study the impact of different levels of task correlation 
on the model performance. Additionally, to add flexibility and allow the variance of each 
task, i.e., 𝛀𝑖𝑖 = 𝜎𝑖
2, to be different, we randomly choose 𝜎𝑖 ∈ {1,2,3,4,5}. Other parameters 
of the experiments in this section are held constant so that the impact of different levels of 
task correlation can be seen clearly (i.e., without being confounded with the change of other 
parameters). Specifically, 20% of the samples from each task are used for training and the 
remaining are used for testing. We consider 20 different tasks. Figure 2 shows the Mean 
Absolute Prediction Error (MAPE) on test data for different levels of task correlation using 
METL in comparison to LMM. There are two observations from the results. First, it is clear 
that METL has a smaller MAPE than LMM over all the different levels of task correlation. 
This shows the advantage of the transfer learning capability of METL in leveraging the 
task correlation to train a more robust model for each task. Second, METL performs better 
with a higher task correlation. This also makes sense because the more the tasks are 
correlated, the more knowledge can be transferred between tasks by METL to help the 




Figure 2: MAPEs of METL and LMM with different levels of task correlation 𝝆𝜴 
(reduction of MAPE by METL over LMM is shown as a percentage) 
 
2.4.2 Study of the impact of task number on model performance  
We consider scenarios with 5, 20, and 50 tasks. 𝜌Ω = 0.5 in all the scenarios so that 
we can separate the effect of task number from task correlation. Other parameters are kept 
the same as Section 2.4.1. Figure 3 shows the result. METL has a smaller MAPE than 
LMM across all the different numbers of tasks. Also, the MAPE of METL decreases as 
there are more tasks to model together, whereas having more tasks does not help improve 




























     Figure 3: MAPEs of METL and LMM with different numbers of tasks 
 
2.4.3 Study of the impact of sample size on model performance  
We consider sample sizes of 20, 50, and 80 from each task. 𝜌Ω = 0.5 and task 
number is set to be 20. Figure 4 shows the result. METL has a smaller MAPE than LMM 
across all the different numbers of tasks. The MAPEs of both methods decrease as the 
sample size increases, which is expected. The advantage of METL is more obvious with a 
smaller sample size due to its transfer learning capability that compensates for sample 




























Figure 4: MAPEs of METL and LMM with different sample sizes 
 
 
2.4.4 Computational time comparison between models 
For all the experiments performed in Section 2.4.1-2.4.3, we recorded not only the 
MAPE on test data as shown in Figures 2-4, but also the runtime of model training. Tables 
1, 2, and 3 show the average runtime over 100 repetitions of METL for the setups in Section 
2.4.1-2.4.3, respectively, in comparison with LMM. All the experiments are performed on 
a desktop computer with Intel Core i7-7700HQ CPU and 16.0 GB RAM using MATLAB 
2018a. There are several observations: 1) Table 1 shows that METL runs slower than LMM 
with lower task correlation, but it runs faster when task correlation becomes higher. This 
is because highly correlated tasks make the 𝛀 estimation converge quicker. 2) Table 2 
shows that both methods run slower with more tasks. This makes sense because more tasks 




























especially with a large number of tasks, e.g., 50, because of the need for accounting for and 
consequently estimating the task correlation encoded in the 𝛀 matrix. This is the price to 
pay to gain higher prediction accuracy. 3) Similar observation can be obtained from Table 
3. Finally, we want to point out that scale of the training runtime of METL (<3 minutes for 
the slowest experiment) is adequate for telemonitoring applications because the frequency 
of model training and deployment needed by such applications in every few weeks. A 
higher frequency would not be too necessary because severity of the disease (e.g., PD) does 
not change in such a high pace.  
 























Table 3. Runtimes of training METL and LMM with different Sample size 
 
 
2.5 Application in Telemonitoring of Parkinson’s Disease (PD) 
In this section, we illustrate an application of METL to monitor the progression of 
PD using data collected by the mPower app installed on patients’ iPhones. The mPower 
app, using Apple’s ResearchKit library, was launched in March 2015 for an observational 
smartphone-based telemonitoring study of PD (Bot et al. 2016). The mPower app collects 
frequent information about the daily activities of PD patients to inform status and severity 
of their disease progression. For each participant to the mPower study, he/she needs to 
conduct the following steps before starting to contribute data, including downloading of 
the app from Apple store, self-navigating through the eligibility criteria (18 years of age or 
older, live in the United States, comfortable reading and writing on iPhone in English), and 
performing an interactive e-consent process (http://sagebase.org/pcc/). Ethical oversight of 
the study was obtained from Western Institutional Review Board. Figure 5 provides a 










Figure 5: Diagram of participant enrollment process prior to data collection in the 
mPower study (Bot, B.M. et al. 2016) 
 
Once in the mPower app, participants were presented with four separate activities 
(referred to as ‘memory’, ‘tapping’, ‘voice’, and ‘walking’), which they could complete 
three times a day. Among the four activities, we primarily focus on the tapping activity in 
this study because tapping captures movement disorder that is a well-known symptom of 
PD (Lainscsek et al. 2012; Lee et al. 2016). The mPower app measures the dexterity and 
speed of each participant’s tapping activity. Specifically, participants are instructed to use 
two fingers on the same hand to alternatively tap two stationary points on the screen for 
20 seconds. The accelerometer on the smartphone can collect the participant’s activity on 
a quantitative scale as time series signals.  
The most commonly used instrument to quantify PD severity is the UPDRS, which 
is a survey given to patients to check PD related symptoms. More recently, a subset of 
questions, the Movement Disorder Society Universal Parkinson Disease Rating Scale 
Understand 
English?
Live        
in US?





(MDS-UPDRS), was released by the Movement Disorder Society (Goetz et al. 2007). A 
total score of 64 on MDS-UPDRS represents the worst disability and a zero score indicates 
no disability. MDS-UPDRS is typically collected in a specialized clinic that requires 
patients’ physical presence. If it could be predicted remotely and accurately using the 
patient’s smartphone-collected tapping signals, disease severity and progression could be 
more closely monitored, and treatment intervention could be performed more timely and 
effectively. To enable test of this hypothesis, the mPower study also collects MDS-UPDRS 
scores of participants monthly.  In order to match up with the frequency of data collection 
on the tapping activity, which is daily, daily MDS-UPDRS values were obtained by linear 
interpolation. A linear trend of UPDRS as PD progresses has been validated in a number 
of previous studies (Chanand Holford 2001; Schüpbach et al. 2009; Tsanas et al. 2010).  
We include a subset of 37 PD patients from the mPower study in our present case 
study. These are the patients who have MDS-UPDRS scores monthly for at least three 
months and complete daily tapping time series data. Each patient has 103 to 522 
observations. To use METL to build a predictive model for each patient’s MDS-UPDRS 
score using tapping data, 45 features are first extracted from the tapping time series. These 
features were chosen from Taylor et al. 2005, Arora et al. 2015, and Kassavetis et al. 2016. 
Taylor et al. (2005) shows that the kinematics of a repetitive alternating finger-tapping task 
using Quantitative digitography (QDG) variables correlated with the UPDRS motor score. 
Arora et al. (2015) develops summary measures that quantify the tapping speed, rhythm, 
inter-tap interval, fatigue, and tremor using finger tapping data. Kassavetis et al. (2016) 
also presents several tapping-related features. To remove redundant and noise features, we 
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perform feature screening by cross-referencing three alternative approaches: 1) correlation 
between each feature and MDS-UPDRS; 2) p-value of the fixed effect for each feature in 
univariate testing; 3) Akaike Information Criterion (AIC) for the random effect of each 
feature. Finally, nine features are selected, which are: Average inter-tap interval, median 
drift in the left button, standard deviation of inter-tap intervals, Coefficient of variation of 
inter-tap intervals, Autoregressive coefficient (lag=1) of inter-tap intervals, mean absolute 
deviation of drift in the right button, minimum of drift in the left button, minimum of drift 
in the right button, and spatial correlation between the hits. The nine features are used as 
predictors for both fixed and random effects. Furthermore, considering that demographic 
information also plays a role in predicting PD severity, we add age and gender as additional 
fixed effect predictors.  
To demonstrate the utility of METL, we perform the following experiments: In 
Section 2.5.1, we show the performance of METL with different training sample sizes. In 
Section 2.5.2, we would like to assess METL under two extreme conditions: 1) only a few 
samples are available for training, and 2) no sample is available for training, for a particular 
patient. Performance under these conditions represents the capability of a predictive model 
for enabling early start of the telemonitoring process, which is important for early 
intervention. In all the experiments, we compare the performance of METL with a range 
of benchmark methods: 
• LMM 
• One-model-fits-all (OMFA) methods, which train a single predictive model by 
pooling all the patients’ data. We include commonly used algorithms for building 
49 
 
a predictive model, such as linear regression, Gaussian process (GP) regression, 
regression tree, ensemble regression tree, and support vector regression (SVR). 
For each algorithm, we use Bayesian optimization to find the best tuning 
parameter(s). 
• One-model-each-patient (OMEP) methods, which train one fixed effect model 
for each patient separately. We include commonly used algorithms such as linear 
regression, Gaussian process (GP) regression, regression tree, ensemble 
regression tree, and support vector regression (SVR). 
 
2.5.1 Performance comparison under different training sample sizes  
We include 10%, 50%, and 80% of the observations from each patient in training 
and the remaining in testing. Table 4 shows the MAPE on test data by METL (last row) 
and benchmark models. It is clear that two mixed effects models, LMM and METL, 
perform the best among all the methods. METL performs better than LMM especially when 
the sample size is small.  
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Table 4. MAPEs of different methods under different training sample sizes 
 
 
2.5.2 Performance comparison under extreme conditions representing capability for early 
start of telemonitoring   
Accumulation of training samples takes time. A typical PD patient visits a 
specialized clinic to have his/her UPDRS score taken every few months. This means that 
many years would have to pass before a predictive model can be built that uses his/her 
smartphone-collected activity data to predict the UPDRS. Therefore, the fewer samples a 
predictive model needs in training, the sooner the patient can be put on telemonitoring to 
enjoy the benefit. In this section, we consider one extreme condition in terms of the training 
sample size: there is no samples for training. Each patient is considered as a test patient 
and all the other 36 patients are included in training. METL is trained for the each of the 
36 patients. The fixed effect model is shared by all the 36 patients and therefore is used to 
predict on the test patient. As shown in Table 5, METL performs the best among all the 
models. The fact that METL performs the best even with no sample available for test 
 (OMFA) Linear regression 5.11 5.05 4.94
 (OMFA) Regression tree 4.34 2.38 1.81
 (OMFA) Support vector regression 5.02 5.01 4.95
 (OMFA) GP regression 3.70 2.26 1.82
 (OMFA) Ensemble 4.31 3.46 3.38
 (OMEP) Linear regression 4.70 4.21 4.09
 (OMEP) Regression tree 4.23 2.02 1.56
 (OMEP) Support vector regression 4.53 4.11 4.00
 (OMEP) GP regression 3.47 1.91 1.57
 (OMEP) Ensemble 4.06 2.68 2.39
 LMM 2.48 1.67 1.44






patients indicates that although the transfer learning mechanism is encoded in the random 
effects of METL, improving the random effects estimation also help improves the fixed 
effects estimation. 
 











 (OMFA) Linear regression 5.87
 (OMFA) Regression tree 6.99
 (OMFA) Support vector regression 5.84
 (OMFA) GP regression 5.80
 (OMFA) Ensemble 6.27
 (OMEP) Linear regression N/A
 (OMEP) Regression tree N/A
 (OMEP) Support vector regression N/A
 (OMEP) GP regression N/A








ACCURATE PATIENT-SPECIFIC MACHINE LEARNING MODELS OF 
GLIOBLASTOMA INVASION USING TRANSFER LEARNING 
 
3.1 Background 
Surgical debulking and radiation therapy represent first-line treatments for 
Glioblastoma (GBM) that rely heavily on image guidance to delineate tumor from adjacent 
non-tumoral brain. Contrast-enhanced MRI (CE-MRI) currently serves as the clinical 
standard for image guidance, but its diagnostic accuracy remains limited. Specifically, CE-
MRI localizes contrast enhancing tumor for surgical resection and/or biopsy but poorly 
identities non-enhancing invasive tumor in the surrounding T2W/FLAIR abnormality 
(Sarkaria, J.N. et al. 2017; Barajas Jr, R.F. et al. 2010; Hu, L.S. et al. 2015). This invasive 
tumor segment can represent a substantial proportion of overall burden for many GBM 
tumors and contributes to recurrent disease and poor survival if left unresected (Baldock, 
A.L. et al. 2014; Price, S.J. et al. 2006; Hu, L.S. et al. 2017). In addition to surgical 
guidance, CE-MRI fails to localize non-enhancing tumor during dosimetric radiation 
treatment planning. To compensate, most radiation oncologists must apply submaximal 
doses across the entire non-enhancing T2/FLAIR volume, which risks toxicity to normal 
brain and undertreatment of non-detected bulk tumor (Corwin, D. et al. 2013; Pafundi, D.H.  
et al. 2013). These issues underscore the need to improve the image-based detection and 
targeted treatment of the non-enhancing tumor segment in GBM. 
Advanced MRI techniques can help characterize non-enhancing tumor by 
measuring an array of biophysical features that complement CE-MRI.  These include tissue 
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cell density on diffusion-weighted imaging (DWI) (Barajas Jr, R.F. et al. 2010; Ellingson, 
B.M. et al. 2010), white matter infiltration on diffusion tensor imaging (DTI) (Stadlbauer, 
A. et al. 2006; Barajas Jr, R.F. et al. 2010; Mohsen, L.A. et al. 2013) and microvessel 
morphology on Dynamic Susceptibility Contrast (DSC) Perfusion MRI (Barajas Jr, R.F. et 
al. 2010; Hu, L.S. et al. 2009; Hu, L.S. et al. 2012a; Hu, L.S. et al. 2012b). Multiple studies 
have used image-guided biopsies to compare these advanced MRI features with tumor cell 
density (TCD) in a spatially accurate manner (Hu, L.S. et al. 2015; Price, S.J. et al. 2006; 
Ellingson, B.M. et al. 2010; Stadlbauer, A. et al. 2006; LaViolette, P.S. et al. 2014; Chang, 
P.D. et al. 2017; Eidel, O. et al. 2016; Barajas Jr, R.F. et al. 2012; Sadeghi, N. et al. 2008; 
Price, S.J. et al. 2011; Beppu, T. et al. 2005; Durst, C.R. et al. 2014). These studies have 
revealed promising trends between MRI signal and tumor abundance, but also surprising 
discrepancies in correlation between studies.  For instance, some groups have reported that 
higher TCD correlates negatively with lower fractional anisotropy (FA) on DTI, 
presumably from greater white matter track disruption (Price, S.J. et al. 2006; Stadlbauer, 
A. et al. 2006).  Yet, opposite (positive) correlations between FA and tumor content have 
also been reported (Beppu, T. et al. 2005).  Similarly, published studies have differed on 
whether TCD correlates negatively or positively with mean diffusivity (MD) measures on 
DWI (Ellingson, B.M. et al. 2010; Stadlbauer, A. et al. 2006; Chang, P.D. et al. 2017; 
Sadeghi, N. et al. 2008). These discrepancies present obvious challenges for developing 
generalized MRI-based models to prospectively quantify TCD and extent of invasion. 
We hypothesize that the relationship between MRI signal (for any given contrast) 
and regional TCD demonstrates patient-to-patient variability within a given cohort. This 
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may underlie the aforementioned discrepancies among published reports in the literature.  
In this study, we set out to quantify interpatient variability and to determine whether it can 
strengthen predictive accuracy of MRI-based models for quantifying TCD and invasion.  
Specifically, we have developed a Transfer Learning (TL) approach that quantifies 
concordance and variability of MRI-histologic relationships across patients. TL builds one 
model for each patient to account for potential interpatient variabilities in MRI-histologic 
relationships, while coupling the estimation processes of each patient-specific model to 
allow for knowledge transfer between models. As proof of concept, we train and cross-
validate this TL approach in a cohort of primary GBM patients using multi-parametric MRI 
and spatially-matched image-guided biopsies. Our overarching goal is to optimize 
predictive models that guide targeted treatment for the problematic non-enhancing tumor 
segment of GBM. 
 
3.2 Development of MRI-based Transfer Learning Algorithm 
3.2.1 Acquisition and Processing of Clinical MRI and Histologic Data 
Patient recruitment: We recruited patients with clinically suspected primary GBM 
undergoing preoperative stereotactic MRI for first-line surgical resection prior to any 
treatment, as per our institutional review board protocol. All patients provided written and 
informed consent prior to enrollment.  The patient cohort presented here has also been 
described in previous studies (Hu, L.S. et al. 2015; Hu, L.S. et al. 2017).  
Pre-operative MRI acquisition protocol:  We acquired pre-operative 3T MRI (Sigma HDx; 
GE-Healthcare, Milwaukee) within 1 day of stereotactic surgery, including T2-Weighted 
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(T2W), T1-Weighted (T1W) precontrast, and T1W post-contrast (T1+C) sequences (Hu, 
L.S. et al. 2012a; Hu, L.S. et al. 2015; Hu, L.S. et al. 2017). T1+C images were acquired 
after completion of Dynamic Susceptibility Contrast (DSC) Perfusion MRI (pMRI) 
following total Gd-DTPA (gadobenate dimeglumine) dosage of 0.15 mmol/kg (Hu, L.S. et 
al. 2012b; Hu, L.S. et al. 2015; Hu, L.S. et al. 2017). In brief, for the DSC protocol, we 
administered intravenous (i.v.) preload dose (0.1 mmol/kg of Gd-DTPA) to minimize T1W 
leakage errors, after which we administered a second i.v. bolus injection (0.05 mmol/kg 
Gd-DTPA) during the 3-minute DSC acquisition (Gradient-echo Echo-planar-imaging 
(EPI): TR/TE/flip angle=1500ms/20ms/60o, matrix=128x128, thickness=5mm) (Hu, L.S. 
et al. 2012b; Hu, L.S. et al. 2015; Hu, L.S. et al. 2017). We derived post-contrast T2*W 
images (EPI+C) from the initial source DSC volume (Hu, L.S. et al. 2015; Durst, C.R. et 
al. 2014). Diffusion Tensor Imaging (DTI) acquisition consisted of Spin-Echo EPI 
[TR/TE=10000/85.2ms, matrix=256x256; FOV=30cm, thickness=3mm, 30 directions, 
ASSET, B=0,1000] (Hu, L.S. et al. 2015; Hu, L.S. et al. 2017).  
 
Surgical biopsy: Neurosurgeons used T1+C and T2W imaging to guide stereotactic 
biopsies following the smallest possible diameter craniotomies to minimize brain shift, as 
previously described (Hu, L.S. et al. 2015; Hu, L.S. et al. 2017). On average, we collected 
5-6 tissue specimens from each tumor, selecting targets >1cm apart from both T1+C 
enhancing regions (ENH) and non-enhancing T2W hyperintense (so called brain-around-
tumor, BAT) in pseudorandom fashion, based on clinical feasibility as per clinical protocol.  
The neurosurgeons recorded biopsy locations via screen capture to allow subsequent 
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coregistration with multiparametric MRI datasets.  The neurosurgeon visually validated 
stereotactic imaging locations with corresponding intracranial anatomic landmarks, such 
as vascular structures and ventricle margins, before recording specimen locations. 
 
Histologic analysis and TCD measurements from image-localized biopsies:  Tissue 
specimens (volume=125mg) were flash frozen in liquid nitrogen in the operating suite and 
stored in -80oC freezer until subsequent retrieval for embedding in optimal cutting 
temperature (OCT) compound and sectioning (thickness=4mm) in a -20Co cryostat 
(Microm-HM-550) utilizing microtome blade (Hu, L.S. et al. 2015; Hu, L.S. et al. 2017). 
Hematoxylin and eosin (H&E) stained slides were reviewed blinded to diagnosis by our 
neuropathologist (JME) to assess for tumor content.   Taking into account all visible cells 
(neurons, inflammatory cells, reactive glia, tumor cells, etc.), the percent tumor nuclei (i.e., 
tumor cells relative to all visible cells) were estimated as a percentage (0-100%), rounded 
to the nearest 5th percentile, and recorded for each tissue sample as a +5% range of TCD 
(e.g., 30-40%, 75-85%, etc) (Hu, L.S. et al. 2015; Hu, L.S. et al. 2017).  This method served 
as a compromise between the resolution of TCD measurements and the precision of 
neuropathologist estimates.  
 
Image signal normalization, DSC and DTI analysis, image coregistration, and Region of 
Interest (ROI) analysis: We normalized the signal for T1+C, T2W, and EPI+C image 
datasets using the Simple Insight Segmentation and Registration Toolkit (SimpleITK 
v1.0.1) (Lowekamp, B.C. et al. 2013) in Python (v3.6.2). The CurvatureFlow algorithm 
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was applied to remove image noise (Sethian, J.A., 1999) and the N4ITK algorithm to 
correct for image intensity nonuniformity bias that could be due to factors such as local 
magnetic field heterogeneity (Tustison, N.J. et al. 2010). Following these corrections, the 
cerebrospinal fluid (CSF) of the lateral ventricles was used as a reference tissue to 
normalize the intensity distributions of each dataset using a previously described linear 
scaling process (Mitchell, J.R. et al. 1997). For DTI we generated mean diffusivity (MD) 
and fractional anisotrophy (FA) maps (Price, S.J. 2006).  For DSC, we generated relative 
cerebral blood (rCBV) maps using IB Neuro (Imaging Biometrics, LLC), employing 
leakage correction (Hu, L.S. et al. 2015; Boxerman, J.L. et al. 2006) and white matter 
normalization (Hu, L.S. et al. 2015; Hu, L.S. et al. 2017). We coregistered all images using 
ITK tools (www.itk.org) and IB Suite (Imaging Biometrics, LLC), using the DTI B0 
anatomical volume as the coregistration target (Hu, L.S. et al. 2012b; Hu, L.S. et al. 2015; 
Hu, L.S. et al. 2017). A board-certified neuroradiologist (LH) placed (8x8 voxel) regions 
of interest (ROIs) for all coregistered multi-parametric MRI datasets at the stereotactic 
biopsy locations (Hu, L.S. et al. 2012b; Hu, L.S. et al. 2015; Hu, L.S. et al. 2017). We  
measured mean signal values within ROIs for all MRI contrasts to correlate with spatially-
matched estimates of TCD from corresponding biopsies.  
 
3.2.2 Statistical Analysis and Predictive Modeling 
Univariate statistical analysis and predictive modeling:  To broadly survey potential 
associations between MRI signal and TCD, we performed univariate analysis using linear 
regression and pearson correlation (r) for each contrast (e.g., T1+C, rCBV, etc) against 
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spatially-matched biopsies across the entire patient cohort.  We used false discovery rates 
(FDR) to adjust for multiple testing (Benjamini, Y. and Hochberg, Y. 1995). To quantify 
intersubject variability, we also plotted MRI signal vs TCD within each patient separately. 
 
Multivariate statistical analysis and predictive modeling using the conventional One-
Model-Fits-All (OMFA) approach: To evaluate the potential complementary function of 
multiple combined MRI contrasts to characterize TCD, we performed multivariable linear 
regression to correlate MRI contrasts with histologic quantification of TCD across all 
biopsies and GBM patients (Chang, P.D. et al. 2017; Durst, C.R. et al. 2014). This entailed 
the conventional approach in which a single static multivariable model was applied 
uniformly to all biopsy samples within the cohort (i.e., OMFA).  We evaluated a range of 
combined MRI contrasts to create various linear regression OMFA models.  For instance, 
a model employing signal intensities on rCBV, MD, and FA would be defined by:  
F(x)=ax1+bx2+cx3+d, where the predicted TCD, F(x), was a linear function of signal 
intensity on rCBV, MD, and FA maps (x1, x2, and x3, respectively).   
 
Transfer Learning (TL) predictive modeling:  Interpatient variability is a known limiting 
factor for many types of predictive models. For instance, a single model applied uniformly 
across all patients within a cohort (i.e., One-Model-Fits-All) is unable to adjust for likely 
interpatient variabilities in MRI-histologic relationships.  In contrast, individual models 
developed for each patient using only that patient’s data (i.e., One-Model-Each-Patient) 
are unable to benefit from general population patterns, and thus inherently suffer from 
59 
 
small sample sizes. TL represents a compromise between the two aforementioned 
approaches. TL is a subfield of ML with various algorithms having been developed to allow 
for knowledge transfer in jointly building different but inherently related models (Weiss, 
K. et al. 2016; Pan, S.J. and Yang, Q., 2010). We have previously published a TL algorithm 
under the Bayesian framework (Zou, N. et al. 2015). Using our TL algorithm, one model 
is built for each patient, but a Bayesian framework is utilized to bias the model parameter 
estimation process towards the population pattern in the case where the individual data is 
not sufficient to precisely determine the individual’s variation. In essence, the population 
pattern represents a generalized model, and TL uses each patient’s own MRI and biopsy 
data to modify that generalized model to more appropriately fit that particular individual 
patient. Thus, TL models are able to account for potential variabilities in MRI-histologic 
relationships across different patients, while also coupling the estimation processes of each 
patient-specific model to allow for knowledge transfer between models.   
 
Transfer Learning theory and methodology:  TL methodology is built upon a Bayesian 
parameter transfer (BPT) model (Zou, N. et al. 2015). To briefly explain the mathematical 
details of our TL algorithm, assume 𝑁 number of patients in a training dataset and a linear 
model between imaging features and cell density for patient 𝑘, i.e., 𝐲𝑘 = 𝐗𝑘𝐰𝑘 + 𝛆𝑘, 𝑘 =
1, … , 𝑁. 𝐲𝑘, consisting of TCD measurements for 𝑛𝑘 biopsy samples. 𝐗𝑘 consists of MRI 
features for biopsy samples. 𝐰𝑘  consists of model coefficients yet to be estimated. 𝛆𝑘 
consists of random errors following a Gaussian distribution. To make the Gaussian 
distribution appropriate, we transform the original TCD measurement (range, 0-1) using a 
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sigmoid function. Furthermore, to couple models from different patients, we adopt a 
Bayesian framework and assume that the patient-specific model coefficients, 𝐖 =
(𝐰1, … ,𝐰𝐾), share the same prior distribution, i.e.,  
                    𝑝(𝐖|𝛀,𝚽, 𝑏) ∝ ∏ 𝐿𝑎𝑝𝑙𝑎𝑐𝑒(𝐰𝑘; 𝑏)
𝐾
𝑘=1 ×𝑀𝑁(𝐖;𝟎,𝛀, 𝐈).                      (3.1)              
𝐿𝑎𝑝𝑙𝑎𝑐𝑒(𝐰𝑘; 𝑏) is a Laplace distribution to facilitate sparsity in model estimation (i.e., to 
produce a parsimonious model for better interpretability) (Tibshirani R. 1996). 
𝑀𝑁(𝐖;𝟎,𝛀, 𝐈)  is a zero-mean matrix-variate normal distribution. Specifically, the 
covariance matrix, 𝛀, encodes the correlation between different patients. 
Furthermore, given the prior distribution in (3.1) and the likelihood based on the training 
data, 𝑝(𝐲𝑘|𝐗𝑘, 𝐰𝑘)~𝑁(𝐲𝑘; 𝐗𝑘𝐰𝑘, 𝜎
2𝐈), we can obtain the posterior distribution of 𝐖 as  
                  𝑝(𝐖|{𝐲𝑘, 𝐗𝑘}𝑘=1
𝐾 , 𝛀,𝚽, 𝑏) ∝ 𝑝(𝐖|𝛀,𝚽, 𝑏)∏ 𝑝(𝐲𝑘|𝐗𝑘, 𝐰𝑘)
𝑁
𝑘=1                     (3.2) 
Then, the Maximum-A-Posteriori (MAP) estimator for 𝐖 can be obtained by solving the 
following optimization problem: 
 ?̂?, ?̂? = argmin 
𝐖,𝛀
{∑ ‖𝐲𝑘 − 𝐗𝑘𝐰𝑘‖2
2𝑁
𝑘=1 + 𝜆1‖𝐖‖1 + 𝜆2(𝑄𝑙𝑜𝑔|𝛀| + 𝑡𝑟(𝐖𝛀
−1𝐖𝑇))}      (3.3) 
Here, ‖∙‖2 and ‖∙‖1 denote the ℓ
1 and ℓ2 norms, respectively. 𝜆1 ≥ 0 and 𝜆2 ≥ 0 are two 
regularization parameters to control the sparsity and the amount of knowledge transferred 
between the models of different patients, respectively. (3.3) is a TL model in the sense that 
it allows a joint estimation of patient-specific model coefficients 𝐰𝑘, 𝑘 = 1, … , 𝑁. The 
most appealing part of the TL model in (3.3) is that it does not require a pre-specification 
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on the correlation between patients, 𝛀, but can estimate it in a data-driven manner. To solve 
the optimization problem in (3.3), i.e., to estimate 𝐖  and 𝛀 , we adopt an efficient 
alternating algorithm that estimates 𝐖 and 𝛀 iteratively (Zou, N. et al. 2015; Idier, J. ed. 
2013; Zhang, Y. and Yeung, D.Y. 2012). That is, given 𝛀, the optimization problem with 
respect to 𝐖 is convex and is solved using the accelerated gradient algorithm (Liu, J. et al. 
2009). Given 𝐖, 𝛀 can be solved analytically. This iterative algorithm is guaranteed to 
converge. 
 
Domain selection: To apply a TL model to each patient, we need to decide the subset of 
other patients to transfer information to the modeling of the target patient. This is known 
as domain selection in TL. In our analysis, we define the subset of “transferrable” patients 
to be those who have a positive rCBV-density correlation, because a positive correlation is 
confirmed by imaging theory and the literature (this is true for our data – the rCBV-density 
correlation over all 82 samples is 0.33). An integration of domain knowledge and machine 
learning model in a unified framework can help to achieve an accurate patient-specific 
model for GBM patients. Therefore, when deciding what other patients to transfer from for 
modeling the rCBV-density relationship of a target patient, we only select patients who 
have a positive rCBV-density correlation to transfer from. For example, when modeling a 
patient in Figure 7, we transfer from all other patients except EB and JTy. Using this 
approach, the LOOCV Pearson correlation between the predicted and true density over the 
73 samples from 14 patients (including EB and JTy) is 0.49. Interestingly, the LOOCV 
Pearson correlation on EB and JTy is very high, 0.85. 
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Leave-one-out cross-validation (LOOCV): To reduce overfitting, we employed LOOCV 
for all OMFA and TL model training.  Briefly, all samples but one (randomly selected 
within each patient) were used to train the predictive model, while the excluded sample 
served as the test case to generate predicted TCD. We repeated this so that all 82 samples 
served as the test case (Hu, L.S. et al. 2015; Brown, R. et al. 2008). We then plotted model-
predicted TCD against actual TCD for all biopsies to determine cross-validated Pearson 
Correlation coefficients (r) and mean absolute error (MAE) rates (difference between 
predicted vs actual TCD) for each model. 
 
3.3 Application of Tumor Content Density Prediction on GBM  
3.3.1 Experiments 
Patients and biopsy samples:  We collected 82 image-recorded biopsy samples 
(median=4∕patient, range=2∼14) from 18 primary GBM patients (9∕9=females∕males, 
median age=60, range=18∼81yrs). We collected ≥ 3 biopsies from 14∕18 patients.   
OMFA Univariate and multivariate correlations between tumor cell density (TCD) and 
MRI:  We performed univariate analysis (Table 6) across all 82 samples comparing TCD 
with the six MRI features individually.  
We found significant correlations for T1+C (r=0.36 p<0.001), rCBV (r=0.33 
p<0.0001), and FA (r= −0.24 p<0.03), although only T1+C and rCBV remained 
significant after correcting for multiple comparisons (p = 0.01). Our observed T1+C 
correlation with TCD supports the long held assumption that regions of MRI enhancement 
(and higher T1+C signal) generally correspond with higher tumor content compared to  
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T1+C* + 0.36 < 0.001 0.01 
T2W + 0.13 0.25 0.38 
rCBV * + 0.33 < 0.001 0.01 
EPI+C − 0.02 0.85 0.85 
FA − 0.24 0.03 0.06 
MD + 0.03 0.78 0.85 
*denotes statistical significance after correcting for multiple comparisons 
peripherally non-enhancing regions (with lower T1+C signal) (Efron B. et al. 2004). This 
underlies the clinical rationale for guiding surgical cytoreduction based on MRI 
enhancement.  However, as non-enhancing regions, by definition, lack MRI enhancement, 
then T1+C would presumably have much lower correlation with TCD within non-
enhancing regions containing invasive tumor content. In fact, separate subgroup analysis 
(Table 7) showed much lower correlation values between T1+C and TCD when restricted 
to only non-enhancing biopsy samples. Meanwhile, the same subgroup analysis showed 
more consistent rCBV correlations across enhancing and non-enhancing biopsy subgroups, 
suggesting the potential utility of rCBV as a biomarker for both tumor segments. We also 
address any potential risks of overfitting by performing LOOCV to estimate the predictive 
performance of rCBV for quantifying TCD.  Using the generalized One-Model-Fits-All 
(OMFA) approach, we generated a single variable linear regression model, with rCBV as 
the sole predictor input, and plotted predicted vs actual TCD (n=82 samples).  This  
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Table 7. One-Model-Fits-All vs. Transfer Learning for various MRI model predictors.  
  Predictors for Model 
One-model-fits-all (OMFA) 
LOOCV (r) and (MAE) 
Transfer Learning (TL) 
LOOCV (r) and (MAE) 
 rCBV 0.27    17.79       0.53    15.19 
 rCBV,EPI+C 0.25   18.03      0.63    11.65 
 rCBV,FA 0.34 17.24      0.58    11.31 
 rCBV,MD 0.28 17.74      0.60    11.93 
 rCBV,T1+C 0.33 16.69      0.69    11.15 
 rCBV,T2W 0.26 17.96      0.59    12.30 
 rCBV,FA,MD 0.32 17.47      0.66    11.93 
 rCBV,T1+C,T2W 0.35 16.61      0.75      9.03 
 rCBV,T1+C,FA 0.39 16.55      0.73      9.07 
 rCBV,T1+C,MD 0.35 16.77      0.74      9.41 
 rCBV,T2W,FA 0.32 17.47      0.64    10.94 
 rCBV,T2W,MD 0.26 18.02      0.64    11.15 
 rCBV,T1+C,FA,MD 0.37 16.78      0.85      6.73 
 rCBV,T2W,FA,MD 0.30 17.68      0.69    10.95 
 rCBV,T1+C,T2W,FA 0.37 16.79      0.73      9.41 
 rCBV,T1+C,T2W,MD 0.34 16.88      0.78      7.01 
 rCBV,T1+C,T2W,FA,MD 0.35 17.05      0.88      5.66 
rCBV,T1+C,T2W,FA, MD, 
EPI+C 





generalized OMFA approach (based on rCBV alone) demonstrated poor performance, with 
low correlation coefficient (r=0.27) and high error (MAE=17.79%) (Table 3.2).  We then 
evaluated other MRI features (combined with rCBV) using multi-variable linear regression 
analysis. Regardless of the combination of MRI features (with rCBV), the generalized 
multivariate OMFA models failed to significantly improve performance (Table 3.2). 
 
Individualized patient plots and interpatient variability:  To investigate interpatient 
variability, we separately plotted MRI signal vs TCD for each of the 14 (of 18) patients 
that contributed ≥  3 separate biopsies (which allowed for LOOCV, as described in 
methods above). The other 4 patients contributed < 3 biopsies, which was insufficient for 
LOOCV analysis.  Patient-by-patient plots are also shown in Figure 8-15. Of the MRI 
correlations with TCD, rCBV demonstrated the greatest consistency across patients, with 
13/14 patients (92.5%) having a positive correlation (r >0.00), although these varied in 
strength from patient to patient (range of r=0.07 to r=0.95) (Figure 8).  Conversely, FA 
correlations showed greater variability (r= −0.75 to r = +0.78), with only 57.1% (8/14) 
of patients having negative correlations with TCD (vs. 42.9% with positive correlation) 
(Figure 9).  MD correlations were also highly variable (range r= −0.96 to r= +0.78), with 
50% of patients split between negative and positive correlations (Figure 10).  These data 
suggest that while certain MRI features may be highly correlated with tumor content in a 
particular patient (or subset of patients), other patients may exhibit weaker or even opposite 
correlations that mask the overall effect in group analysis. We recognize that some of these 
individual plots may have small sample sizes that limit the statistical confidence of the 
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correlation coefficients. And so, the individual plot coefficient values themselves should 
be viewed with this limitation in mind. At the same time, the directionality of the individual 
correlation plots (i.e., positive vs negative) appear to show distinct populational trends, and 
we intend to use the results here to illustrate some of the inter-patient variabilities that may 
exist between TCD and imaging measurements. These inter-patient variabilities motivate 
the use of the transfer learning approach detailed in the next section. 
 
Transfer Learning:  Based on the results from univariate analysis and individual scatter 
plots, we prioritized rCBV for training of TL and constrained knowledge transfer from 
patients with an arbitrary threshold for correlation between rCBV and TCD (r >0.10). 
Using LOOCV, the TL model with rCBV as the sole model predictor improved the 
correlation between predicted vs actual TCD (r=0.53, p<0.001, n=82), when compared to 
the generalized One-Model-Fits-All (OMFA) model that also used rCBV as the sole 
predictor (r=0.27 using LOOCV) (Table 7). We then quantified incremental gains from 
adding other MRI contrasts to the rCBV-based TL model. As shown in Table 7, 
individualized transfer learning (TL) models consistently improved correlation coefficients 






Figure 6: Transfer Learning (TL) improves predictive performance for quantifying TCD. 
Scatter plots show the correlations between actual (y-axis) versus model-predicted (x-axis) 
tumor cell densities using multivariable modeling (rCBV, T1+C, MD, and FA) and the 
generalized (A) One-Model-Fits-All (OMFA) versus the individualized (B) Transfer 
Learning (TL) approaches.  
 
Figure 6 shows the scatterplots for actual versus predicted TCD using the highest 
performing TL model, which incorporated rCBV, T1+C, FA, and MD as model predictors.  
After LOOCV, this model achieved a Pearson correlation of r=0.88 (p<0.001) across all 
samples (n=82), which further increased among non-enhancing T2/FLAIR samples alone 
(r=0.94, p<0.001, n=33). Blue and red dots denote biopsy samples from enhancing 
(n=49) and non-enhancing (n=33) regions, respectively. Regression lines and Pearson 
correlations (r) are shown for all 82 samples (black lines and text) versus only the 33 non-
enhancing samples (red lines and text). By comparison, correlations using TL are 
significantly higher compared to the generalized OMFA approach. The generalized OMFA 
approach, using the same model predictors, achieved much lower correlation coefficients 
for all samples (r=0.39, n=82) and non-enhancing samples alone (r=0.09, n=33).  As 
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shown in Figure 7, the TL model can be used to generate color overlay maps of predicted 
TCD that correspond with actual TCD from spatially matched biopsies throughout different 
non-enhancing regions in the same GBM tumor.    
 
Figure 7: Transfer Learning (TL) maps and multiple biopsies in a 71 y/o primary GBM 
patient. (A-C):  TL-based color map overlay on a T2W image (A) shows predicted regional 
tumor cell density (TCD) ranging from 0-100% (blue to red) throughout the segmented 
tumor region (based on the T2W signal abnormality). Histologic analysis of the top biopsy 
(purple boxes B,C) yielded 90% TCD, corresponding to red regions of high TL-predicted 
TCD (A, purple box). (D-F): TL-based color map (D) from a more caudal T2W slice shows 
blue regions of low TL-predicted TCD (blue/green, purple box), corresponding to 25% 





In this study, we correlated a panel of MRI features with regional tumor cell density 
(TCD) using image-guided biopsies and spatially matched MRI measurements. In 
particular, the advanced MRI features (i.e., rCBV, MD, FA), have been widely published 
for their potential to characterize TCD within the non-enhancing tumor segment of GBM.  
On univariate analysis, we found that rCBV was the only advanced MRI feature to 
significantly correlate with TCD after correcting for multiple comparisons (p=0.01) 
(besides the conventional MRI feature T1+C). This low-moderate positive correlation 
(r=0.33, p<0.001) remains concordant with other published studies on rCBV (Barajas Jr, 
R.F. et al. 2012; Sadeghi, N. et al. 2008; Price, S.J. et al. 2011), which have all consistently 
reported positive correlations with TCD. In contrast, our analysis showed no significant 
correlation for MD. The correlation for FA (r= −0.24) shows a p value of 0.06 after 
correcting for multiple comparisons, which trends toward significance. These results are 
not entirely discordant with the literature, as past studies have lacked general consensus on 
how MD and FA correlate with TCD.  For instance, Stadlbauer, A. et al. (2006) and Price, 
S.J. et al. (2006) reported negative correlations between FA and TCD, while Beppu, T. et 
al. (2005) reported positive correlations.  Similarly,  Ellingson, B.M. et al. (2010) and 
Chang, P.D. et al. (2017) reported negative correlations between MD and TCD, while 
Stadlbauer, A. et al. (2006) reported positive correlations. 
We hypothesize that the correlations observed in our study (as well as in the 
literature) may be impacted by interpatient variability in how MRI signal relates to TCD. 
To gain insight to this variability, we analyzed individualized plots of MRI signal vs tumor 
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content within our cohort.  In keeping with trends in the literature, rCBV correlations were 
highly consistent in regards to direction, with 92.5% of patients showing positive 
correlations. We did, however, observe a wide range of correlation strengths (range, r=
+0.07 to r= +0.95), which explains the low-moderate group correlation.  In contrast to 
rCBV, we observed highly variable correlations for both FA (range, r= −0.75 to r=
+0.78) and MD (range, r= −0.96 to r= +0.78), with conflicting directions across patients. 
These discrepancies echo the discordance among studies in the literature and underscore 
the challenge of using a “one-model-fits-all” approach to generalize heterogeneity across 
patients. 
  TL addresses this challenge by estimating models for each patient by iteratively 
identifying patient similarity and leveraging it for robust model building using a Bayesian 
framework (Zou, N. et al. 2015). Our results strongly suggest that TL should prioritize 
rCBV, given its high interpatient consistency and statistically significant correlations in 
univariate analysis. This assertion is supported further by the consistency of reported rCBV 
correlations in the literature (Barajas Jr, R.F. et al. 2012; Sadeghi, N. et al. 2008; Price, S.J. 
et al. 2011). The application of TL to an rCBV-based model predictor significantly 
improved correlation (r=0.53) compared to the “one-model-fits-all” approach (r=0.27). 
TL further improved performance when combining rCBV with other MRI features in 
multivariate fashion (r=0.88), particularly for the non-enhancing T2/FLAIR samples 
(r = 0.94). This represents a substantial increase in performance compared to the 
conventional “one-model-fits-all” approach in our study (r=0.30) (Table 7) and those 
previously published (Chang, P.D. et al. 2017; Durst, C.R. et al. 2014).  
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Of note, the TL method presented here requires MRI and histologic input from at 
least two image-localized biopsies (per patient) to make predictive inferences for the 
remaining “unknown” (i.e.,unbiopsied) regions throughout each patient’s tumor. Our 
analysis shows that these patient-specific inputs dramatically increase predictive 
performance for quantifying regional TCD on an individualized basis. While retrospective 
in nature, these results offer proof of concept that TL can help prospectively guide surgical 
biopsy and/or resection in a patient-specific manner. As part of our intraoperative 
workflow, we are currently integrating real-time neuropathologist estimates of TCD 
(adding 2~3 minutes of analysis per sample) from frozen surgical specimens to support 
prospective TL-based neurosurgical guidance. These real-time estimates allow active 
updating of the TL model intraoperatively accomplished in < 5 min given standard 
computing hardware - to guide surgical targeting for the remaining unresected tumor 
regions.  Additionally, individualized TL-based models can also guide dosimetric radiation 
planning in the post-operative setting.  By delineating regional populations of residual non-
enhancing tumor in the otherwise non-specific T2/FLAIR segment, individualized TL-
based maps will facilitate more nuanced radiation planning strategies to prescribe higher 
dose with increasing TCD while sparing dose to normal non-tumoral brain.  
  We recognize several limitations to this study. First, like all other previously 
published reports, our study lacks a dedicated validation set. In fact, the conventional 
approach in the literature has been to report correlation coefficients from training data 
alone, which is prone to overfitting (Hu, L.S. et al. 2015; Price, S.J. et al. 2006; Ellingson, 
B.M. et al. 2010; Stadlbauer, A. et al. 2006; LaViolette, P.S. et al. 2014; Chang, P.D. et al. 
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2017; Eidel, O. et al. 2016; Barajas Jr, R.F. et al. 2012; Sadeghi, N. et al. 2008; Price, S.J. 
et al. 2011; Beppu, T. et al. 2005; Durst, C.R. et al. 2014). By comparison, our study is the 
first to employ more rigorous cross validation testing (through LOOCV) to offset potential 
risks of overfitting, whereby each biopsy sample in our cohort is treated as an “unseen” or 
unknown case to test predictive performance (Hu, L.S. et al. 2015). While cross validation 
strengthens our confidence in these initial findings, prospective validation in future studies 
will ultimately be needed.  Second, we have used neuropathologist estimates of TCD as 
the benchmark measure of tumor content. We believe that this represents a more clinically 
relevant metric compared to total cell density, which can be comprised of both tumoral and 
non-tumoral components (e.g., astrocytes, microglia) (Ellingson, B.M. et al. 2010; Chang, 
P.D. et al. 2017). Nonetheless, we are currently pursuing automated quantification of 
cellular density in our histologic samples (Chang, P.D. et al. 2017). This type of 
standardization will help facilitate TL implementation across different institutions in the 
future. Finally, we recognize that image distortions and brain shift following craniotomy 
could lead to misregistration errors. To compensate, neurosurgeons used small craniotomy 
sizes to minimize brain shift and also visually validated stereotactic image location with 
intracranial neuroanatomic landmarks to help correct for random brain shifts. Rigid-body 
coregistration of multi-parametric imaging also helped reduce possible geometric 
distortions (Barajas Jr, R.F. et al. 2010; Hu, L.S. et al. 2012a; Barajas Jr, R.F. et al. 2012; 
Hu, L.S. et al. 2015). Overall, our experience suggests combined misregistration is 
approximately 1–2mm from both brain shift and registration technique, which is similar to 
that from previous studies using stereotactic needle biopsy (Stadlbauer, A. et al. 2006).  
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Table 8. Pearson correlation coefficients (r) from univariate analysis separately comparing 
the six MRI features with tumor cell density (TCD) for all samples and subgroups of only 
non-enhancing versus only enhancing biopsy samples.  P-values are shown in parentheses.  
 
  
T1+C T2W rCBV EPI+C FA MD 










































Figure 8: Individual patient (A-Q) plots of relative cerebral blood volume (rCBV) vs tumor 
cell density using spatially matched image-localized biopsies.  We generated scatterplots 
for the 14 primary GBM patients in our cohort that underwent at least 3 image-localized 
biopsies from their initial surgery.  There were 4 patients (not shown) that had only 2 
image-localized biopsies each, and were thus excluded from this analysis.  The scatterplots 
for each patient consist of only those patient’s histologic and MRI data and show the 
pearson correlation coefficients (r) for rCBV (x-axis) versus actual tumor cell density (y-
axis) from corresponding spatially matched biopsies.  Nearly all (13 of 14) patients 
demonstrated positive correlations such that rCBV increased with higher tumor cell 




Figure 9: Individual patient (A-Q) plots of Fractional Anisotropy (FA) vs tumor cell density 
using spatially matched image-localized biopsies.  We generated scatterplots for the 14 
primary GBM patients in our cohort that underwent at least 3 image-localized biopsies 
from their initial surgery.  There were 4 patients (not shown) that had only 2 image-
localized biopsies each, and were thus excluded from this analysis.  The scatterplots for 
each patient consist of only those patient’s histologic and MRI data and show the pearson 
correlation coefficients (r) for FA (x-axis) versus actual tumor cell density (y-axis) from 
corresponding spatially matched biopsies.  Compared to rCBV plots in SF1, the direction 
of FA correlations showed greater variability across patients, with only 57.1% (8/14) of 





Figure 10: Individual patient (A-Q) plots of Mean Diffusivity (MD) vs tumor cell density 
using spatially matched image-localized biopsies.  We generated scatterplots for the 14 
primary GBM patients in our cohort that underwent at least 3 image-localized biopsies 
from their initial surgery.  There were 4 patients (not shown) that had only 2 image-
localized biopsies each, and were thus excluded from this analysis.  The scatterplots for 
each patient consist of only those patient’s histologic and MRI data and show the pearson 
correlation coefficients (r) for MD (x-axis) versus actual tumor cell density (y-axis) from 
corresponding spatially matched biopsies.  Compared to rCBV plots in SF1, the direction 
of MD correlations showed greater variability across patients, with 50% of patients split 





Figure 11: Individual patient (A-Q) plots of T1W post-contrast signal (T1+C) vs tumor cell 
density using spatially matched image-localized biopsies.  We generated scatterplots for 
the 14 primary GBM patients in our cohort that underwent at least 3 image-localized 
biopsies from their initial surgery.  There were 4 patients (not shown) that had only 2 
image-localized biopsies each, and were thus excluded from this analysis.  The scatterplots 
for each patient consist of only those patient’s histologic and MRI data and show the 
pearson correlation coefficients (r) for T1+C (x-axis) versus actual tumor cell density (y-
axis) from corresponding spatially matched biopsies.  Similar to rCBV plots in SF1, the 
direction of T1+C correlations showed high consistency across patients, with positive 





Figure 12: Individual patient (A-Q) plots of post-contrast T2*W signal (EPI+C) vs tumor 
cell density using spatially matched image-localized biopsies.  We generated scatterplots 
for the 14 primary GBM patients in our cohort that underwent at least 3 image-localized 
biopsies from their initial surgery.  There were 4 patients (not shown) that had only 2 
image-localized biopsies each, and were thus excluded from this analysis.  The scatterplots 
for each patient consist of only those patient’s histologic and MRI data and show the 
pearson correlation coefficients (r) for EPI+C (x-axis) versus actual tumor cell density (y-







Figure 13: Individual patient (A-Q) plots of T2W signal vs tumor cell density using 
spatially matched image-localized biopsies.  We generated scatterplots for the 14 primary 
GBM patients in our cohort that underwent at least 3 image-localized biopsies from their 
initial surgery.  There were 4 patients (not shown) that had only 2 image-localized biopsies 
each, and were thus excluded from this analysis.  The scatterplots for each patient consist 
of only those patient’s histologic and MRI data and show the pearson correlation 
coefficients (r) for T2W (x-axis) versus actual tumor cell density (y-axis) from 










A NOVEL PRIVACY-PRESERVING POSITIVE TRANSFER LEARNING(P3TL) 




For many aggressive diseases, effective treatment needs close monitoring of the disease 
progression. Conventionally, clinical indicators of the disease progression, such as 
symptoms, biomarkers, and image phenotype, can only be measured with the patient’s 
physical presence in a clinic. This is costly and logistically inconvenient for both the patient 
and medical staff. As a result, insufficient clinical examinations are not uncommon, which 
lead to sub-optimal treatment as the treatment always lags behind the progressing disease. 
To improve this situation, the emerging telemonitoring technology shows great promise. 
Telemonitoring is the use of electronic devices or simply smart phones to remotely monitor 
patients so that patients do not need to come to the clinic. Next, we give an example of 
using telemonitoring for the Parkinson’s disease (PD).  
PD is the second most common neurodegenerative disorder and currently affects 
around seven million people worldwide (Goetz, C.G. et al. 2009). At present, there is no 
available cure, whereas treatment can only alleviate some symptoms and mildly slow down 
progression. Tracking PD progression is important for managing the disease, which is 
typically done by measuring a Unified PD Rating Scale (UPDRS) repeatedly over time. 
However, measuring UPDRS needs the patient’s physical presence in a specialized clinic 
and trained medical professionals to administer the test. This is costly and inconvenient. If 
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a simple surrogate test for UPDRS could be done by each patient on their own at home, 
which has a high correlation with UPDRS, management of PD would be significantly 
advanced and patients’ quality of life would be greatly improved. At-Home Testing Device 
(AHTD) is a recently developed telemonitoring system that enables remote, internet-based 
measurement of PD symptoms especially the vocal symptoms (Dorsey, E. et al. 2007). 
Vocal impairment is a common symptom of PD with ample evidence showing deteriorating 
voice performance correlated with PD progression (J. Holmes, R. et al. 2000; Skodda, S. 
et al. 2009).  
Telemonitoring devices are typically paired up with predictive analytics that 
“translate” the monitoring signals into clinical indicators of the disease progression. In the 
previous PD example, this means building a predictive model between the voice signal 
measured by AHTD and UPDRS. This predictive modeling is not straightforward because 
PD patients are highly heterogeneous in terms of demographics, genetic risk factors, 
comorbidity, staging, and treatment regimen. As a result, each patient has a different voice-
UPDRS relationship, which means that a distinct model should be learned for each patient. 
Learning a patient-specific model faces the difficulty of limited data. Ideally, one would 
want to wait until abundant data has been collected before building the predictive model. 
However, this would need a long time period of tryout experiments for data collection 
before the device could be used to track the patient’s PD progression, thus running the risk 
of missing the opportune time window for treatment. 
To build a patient-specific predictive model with limited data, we propose to use 
Transfer Learning (TL), a machine learning method that can leverage other patients’ 
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information to make up the data shortage when modeling a target patient. However, the 
application of TL for telemonitoring faces two unique challenges: First, for privacy 
protection, it is not allowed to transfer other patients’ data but only the knowledge/models. 
Then, the research question is how to integrate the knowledge/models about other patients 
with the target patient’s specific data. Second, when modeling a target patient, not every 
other patient’s information is helpful. Transfer learning from some patients may hurt the 
modeling of the target patient. This problem is called negative transfer. Therefore, selection 
of an appropriate subset of other patients to transfer from is a critical research question. 
To address the aforementioned challenges, we propose a Privacy-Preserving Positive 
Transfer Learning (P3TL) model that can intelligently select other patients to transfer from 
when modeling a target patient and that does not need disclosure of other patients’ data. 
The main contributions of this chapter are summarized as follows: 
• Theory: P3TL is built upon a Bayesian parameter transfer (BPT) model we proposed 
in a previous publication (Zou, N. et al. 2015), which belongs to the category of 
statistics-sharing privacy-preserving approaches. However, the risk of negative 
transfer for BPT was not assessed previously. In this chapter, we perform theoretical 
study and derive the generalization bound of BPT, which reveals that the risk of 
negative transfer exists in BPT. After confirming the existence, we perform further 
theoretical study to investigate what is the key element in BPT that causes negative 
transfer and identify a sufficient and necessary condition for negative transfer to 
happen. This points out the direction where P3TL can make improvement. Note that 
although negative transfer has been recognized as an important issue by the TL 
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research community, there is a lack of theoretical study on evaluating the risk of 
negative transfer for a TL method and identifying what causes the negative transfer. 
Our work fills in this gap.  
• Algorithm: Driven by the theoretical insights, we extend BPT to a new method, i.e., 
P3TL, which is robust to negative transfer and is privacy-preserving. These features 
make P3TL an excellent model for telemonitoring. To our best knowledge, P3TL is 
the first of its kind that addresses both privacy preservation and negative transfer in 
a unified framework. 
• Real-world application:  P3TL to predicting UPDRS for 42 PD patients using their 
AHTD vocal measurement. P3TL achieves significantly better accuracy compared 
with single learning (SL) and one-model-fits-all (OMFA) approaches. SL refers to 
classic machine learning models that build a predictive model using only the target 
patient’s data without knowledge transfer from other patients. OMFA refers to 
machine learning models built on pooled data across all the patients. We envision 
that the initial success of P3TL on telemonitoring of PD provides great promise of 
using remote sensing devices to improve the monitoring, treatment, and care of many 
aggressive diseases.  
The rest of the chapter is organized as follows: Section 4.2 reviews related work and 
points out limitations. Section 4.3.1 introduces BPT model, which is the basis of 
development for P3TL. Section 4.3.2 performs theoretical study to assess the risk of 
negative transfer for BPT and further identify a sufficient and necessary condition for 
negative transfer to happen. Driven by the theoretical insights from Section 4.3.2, Section 
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4.3.3 develops the P3TL algorithms that are robust to negative transfer. Section 4.4 presents 
simulation experiments. Section 4.5 presents the application of P3TL in telemonitoring of 
PD using real data. Section 4.5 is the conclusion.  
 
4.2 Related Work 
This work intersects with two fields: transfer learning and privacy preserving. In the 
following pages, we review each field: 
 
Transfer Learning 
The overview of TL models are described in Chapter 1. This chapter focuses on the 
application of TL in telemonitoring, which requires a privacy preserving TL method. Under 
this requirement, instance and feature transfer methods are not suitable because they need 
data of the source domains (i.e., other patients) to be “seen” by the target domain (i.e., the 
target patient). Parameter transfer holds the promise for enabling privacy protection. The 
proposed P3TL is a parameter transfer method.  
An important issue with TL is negative transfer. This is the situation when transfer 
learning from a source domain results in a worse model for the target domain than that 
without transfer learning. The latter is a classic machine learning model that uses only the 
data in the target domain, and is typically referred to as a single learning (SL) model. Only 
a few methods have been developed which embrace an explicit consideration to guard 
against negative transfer. Seah et al. (2013) proposed a predictive distribution matching 
(PDM) regularizer to identify and remove irrelevant source samples. Gong et al. (2012) 
proposed a Rank of Domain (ROD) metric to rank sources domains in terms of how 
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suitable they are for helping model the target domain. Duan et al. (2012) proposed a 
Domain Selection Machine (DSM) for selecting source domains to be used to help 
prediction on the target domain. Ge et al. (2014) proposed a two-phase TL framework to 
prevent negative transfer, which first assigned Supervised Local Weight (SLW) to each 
source domain and then built a Reproducing Kernel Hilbert Space (RKHS) classifier for 
the target domain that balanced the prediction error on labeled data and consistency with 
weighted predictions from source domains on unlabeled data.  
In summary, although negative transfer has been recognized as an important issue 
in TL, only limited work has been done so far. The existing methods do not suffice for 
telemonitoring. The methods proposed by Seah et al. (2013) and Gong et al. (2012) fall 
into the categories of instance and feature transfer, respectively, which do not offer the 
privacy-preserving capability. The method by Duan, L. et al. (2012) is conceptually more 
similar to ensemble learning than TL. The method by Ge et al. (2014) is the closest to what 
is needed for telemonitoring. However, the predictive model was built on the RKHS space, 
and therefore it cannot explicitly show the predictor-response relationship to facilitate 
predictor selection and model interpretation. A white-box model is more preferred. 
 
Privacy-preserving techniques 
Privacy-preserving techniques concern statistical analysis on combined data from 
multiple sources/data holders while protecting privacy. The techniques fall into three 
general categories: differential privacy (DP), cryptography, and statistics-sharing 
approaches. DP is a well-known category intended to achieve security on private databases 
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by minimizing the chances of records identification (Dwork et al. 2006; Dwork et al. 2008; 
Duchi, J.C. et al. 2013). The mechanisms of achieving DP mainly include adding Laplace 
noise (Dwork et al. 2006; Chaudhuri, K. and Monteleoni, C. 2009), generating noisy 
histogram and synthetic data (Lei, J. 2011), and functional perturbation (Zhang, J. et al. 
2012). Local DP (Duchi, J.C. et al. 2013) is a more conservative method in which data 
holders do not trust any data collector or analyst. DP has strong theoretical foundation and 
is a well-recognized approach in the privacy-preserving research society. If our objective 
were to build one model for all patients, DP would be a good approach by providing 
theoretical guarantee that not a single patient’s information is identifiable. However, as 
pointed out previously, PD patients are highly heterogeneous and each patient needs a 
different model for the voice-UPDRS relationship. For maximum privacy protection, the 
model building should happen locally for each patient using the specific data possessed by 
the patient him/herself. This unique property of our application makes DP unsuitable.  
Another category of privacy-preserving techniques is cryptography. For example, 
homomorphic encryption (Paillier, P. 1999; Gentry, C. and Boneh, D. 2009) enabled other 
parties to perform computation on the data without possession of the private key. El Emam 
et al. 2012 proposed a regression framework with the Paillier cryptosystem using a number 
of secure building blocks. Cryptography is not suitable for our application due to the same 
reason mentioned above for DP. Additionally, the encryption steps may potentially prolong 
the time for model building/training and model utilization/deployment, which results in 
negative user experience.  
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The third category consists of statistics-sharing approaches. A statistic is a quantity 
computed from raw data. Statistics-sharing approaches study what statistics from each data 
source can be shared to facilitate collaborative modeling while making sure the raw data is 
non-identifiable from the statistics. For example, Du et al. 2004 proposed a Secure 2-party 
Computation (S2C) framework that shared covariance matrices from each data source for 
collaborative regression fitting.  Li et al. 2016 proposed a Local Query Model to share the 
partial gradient of the loss function for collaborative LASSO fitting. The proposed P3TL 
model falls into this category, in which fitted regression coefficients from sources (i.e., 
other patients in our case) are shared with each target patient and integrate with the target 
patient’s specific data to build a more robust predictive model.   
 
4.3 Development of the Proposed P3TL Approach 
4.3.1 Introduction to Bayesian Parameter Transfer (BPT) Model 
 Let X = (X1, … , XQ) denote Q predictors and Y denote the response. Assume that 
the proposed P3TL is built upon a Bayesian parameter transfer (BPT) model we proposed 
in a previous publication (Zou, N. et al. 2015). This section provides an introduction to 
BPT. While the original BPT was proposed as a generic TL model, we will describe it 
within the context of telemonitoring.  
Suppose there are 𝐾 patients. For each patient 𝑖, 𝑖 = 1,… , 𝐾, let 𝐗𝑖 and 𝑌𝑖 be the 
set of 𝑄 predictors and the response variable, respectively. A linear regression has the form 
of y𝑖 = 𝐗𝑖𝐰𝑖 + 𝜀𝑖 , where 𝐰𝑖  contains model coefficients, 𝜀𝑖~𝑁(0, 𝜎
2) . To model the 
relatedness of the 𝐾  patients, we consider that the patient-specific coefficients, 𝐖 =
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(𝐰1, … ,𝐰𝐾), share a common prior:  
                             𝑝(𝐖) ∝ ∏ 𝐿𝑎𝑝𝑙𝑎𝑐𝑒(𝐰𝑖; 𝑏)
𝐾
𝑖=1 ×𝑀𝑁(𝐖;𝟎,𝛀, 𝐈).                       (4.1) 
Here, 𝐿𝑎𝑝𝑙𝑎𝑐𝑒(𝐰𝑖; 𝑏) is a Laplace distribution to impose sparsity on model estimation 
with high-dimensional predictors. 𝑀𝑁(𝐖;𝟎,𝛀, 𝐈) is a zero-mean matrix-variate normal 
distribution with 𝛀 ∈ ℝ𝐾×𝐾 and 𝐈 ∈ ℝ𝑄×𝑄 being the covariance matrices between patients 
and between predictors, respectively.  
Furthermore, we can derive the conditional prior of the coefficients for each patient 
(called the target) given the coefficients for all other patients (called the sources). For 
example, if patient 𝐾 is the target, we can get 
  𝑝(𝐰𝐾|?̃?) ∝ 𝐿𝑎𝑝𝑙𝑎𝑐𝑒(𝐰𝐾; 𝑏) × 𝑁(𝐰𝐾; 𝛍𝐾, 𝚺𝐾).                       (4.2)    
where ?̃? = (𝐰1, … ,𝐰𝐾−1). Integrating (4.2) with the data of the target patient, 𝐱𝐾 and 𝐲𝐾, 
we can get the posterior distribution of 𝐰𝐾 and further derive the Bayesian Maximum A 
Posteriori (MAP) estimator for 𝐰𝐾 as 






2 + 𝜆1‖𝐰𝐾‖1  + 𝜆2 (𝑙𝑜𝑔|𝚺𝐾| + (𝐰𝐾 − 𝛍𝐾)
𝑇𝚺𝐾
−1(𝐰𝐾 − 𝛍𝐾)),               
                                                                                                       (4.3) 
where                      𝛍𝐾 = ?̃??̃?
−1𝛡𝐾,                                                     (4.4) 
                     𝚺𝐾 = (𝜍𝐾 −𝛡𝐾
𝑇 ?̃?−1𝛡𝐾)𝐈.                        (4.5) 




]. That is, 𝛡𝐾  contains covariances 
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between each source and the target patient; ?̃? is the covariance matrix between all source 
patients; 𝜍𝐾 is the variance of the target patients. 𝜆1 and 𝜆2 are tuning parameters. ‖∙‖2 and 
‖∙‖1 are the is the 𝑙2- and 𝑙1-norm, respectively. Transfer learning is enabled by the last 
term in (4.3) in the sense that the minimization pushes 𝐰𝐾  to be close to 𝛍𝐾  which 
represents a weighted sum of coefficients of the source patients according to (4.4). The 
model in (4.3) is a convex optimization problem with given 𝜆1  and 𝜆2 , and can be 
efficiently solved by a convex solver.  
Furthermore, when 𝛍𝐾  and 𝚺𝐾  are unknown, (4.3) can be extended to a more 
general form as: 





2 + 𝜆1‖𝐰𝐾‖1 + 𝜆2(𝑙𝑜𝑔|𝚺𝐾| + (𝐰𝐾 −
𝛍𝐾)
𝑇𝚺𝐾
−1(𝐰𝐾 − 𝛍𝐾)).                                                                                                     (4.6) 
(4.6) can be solved by an iterative algorithm that alternates between solving two sub-
problems: (i) Given 𝛍𝐾  and 𝚺𝐾 , (4.6) becomes (4.3). (ii) Given 𝐰𝐾 , (4.6) becomes an 
optimization with respect to 𝛍𝐾  and 𝚺𝐾 , and can be solved analytically (Zou, N. et al. 
2015).  
Note that BPT is privacy-preserving because it only includes the regression 
coefficients of the other patients in 𝛍𝐾 not their respective raw data. From the coefficients, 
the raw data cannot be retrieved. Since P3TL is built upon BPT, the privacy-preserving 
ability of BPT naturally extends to P3TL. Also note that since the shared regression 
coefficients are a type of statistics, BPT and P3TL belong to the third category of statistics-
sharing privacy-preserving approaches discussed in Section 4.2. 
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4.3.2 Risk of Negative Transfer for BPT 
P3TL is motivated by the risk of negative transfer for BPT and aims to provide a 
better approach to mitigate this risk. In this section, we first derive the generalization bound 
of BPT, which was not studied in the previous BPT paper, and reveal that this risk exists 
in BPT. After confirming the existence, we further investigate what is the key element in 
BPT that causes negative transfer, with purpose of providing concrete guidance on the 
direction where P3TL can make improvement.  
We follow the definition in (Bousquet, O. and Elisseeff, A. 2002) and define the 
generalization bound as deviation of the generalization error to leave-one-out (LOO) error 
on a training set. Without loss of generality, we focus our discussion on the model in (4.3) 
with only the TL term for simplicity of presentation, i.e. 






2 + 𝜆((𝐰𝐾 − 𝛍𝐾)
𝑇(𝐰𝐾 − 𝛍𝐾)),      (4.7) 
For the model in (4.7), let 𝑆 = {(𝒙1, 𝑦1), … , (𝒙𝑛𝑡𝑟 , 𝑦𝑛𝑡𝑟)} be a training set for a target 
patient. The generalization and LOO errors are: 







where 𝑓𝑆 and 𝑓𝑆\𝑖 are BPT on the entire training set and on the subset with the 𝑖-th sample 
left out, respectively. 𝑙 is a loss function for which we focus on the commonly used squared 
loss in this chapter, a.k.a. Mean Squared Prediction Error (MSPE).  
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Theorem 4.1: (generalization bound).  Assume ‖𝒙𝑖‖ ≤ 1  for the training set. Let 
MSPE(𝛍𝐾) be the MSPE of a “complete transfer” model that uses the source patient model 
for the target patient directly without using any data from the target in training. We have 
the following generalization bound for BPT with probability 1 − δ,  









.            (4.8) 
The proof can be found in Appendix (A). Interestingly, the generalization bound is 
influenced by MSPE(𝛍𝐾); larger MSPE(𝛍𝐾) increases the generalization error. This makes 
sense because larger MSPE(𝛍𝐾) means the lack of fit in using the source patient model for 
the target patient’s data, indicating significant difference between the source and target. 
When this happens, BPT’s transfer learning ability may actually harm its performance by 
having a large generalization error. This means that BPT can perform worse on data not 
included in training, such as a separate test set, than a SL model (i.e., one using target 
patient’s data alone without TL from the source). This is when negative transfer happens.  
With Theorem 4.1 confirming the possibility of negative transfer for BPT, our next 
step is to discover what causes the negative transfer. This is discussed in Theorem 4.2, 
prior to which we give the formal definition of negative transfer. 
Definition 4.1 (negative transfer): When 𝜆 = 0 , (7) becomes an SL model. Let 
MSPE𝑡𝑒(0) and MSPE𝑡𝑒(𝜆) be the MSPEs of SL and (7) on a test set, respectively. 𝜆 > 0. 
Negative transfer happens when MSPE𝑡𝑒(𝜆) > MSPE𝑡𝑒(0).   
Theorem 4.2: Negative transfer happens if and only if 𝜆 > 𝜂, where  
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.                                      (4.9) 
Please see the proof in Appendix (A). (4.9) suggests that negative transfer is caused by 𝜆 
being too large, i.e., large than a threshold 𝜂. Two parameters in 𝜂, 𝛼𝑖 and 𝛾𝑖, have not been 
previously defined. We provide their definitions as follows:  
𝛼𝑖  is the 𝑖 -th element (corresponding to the 𝑖 -th predictor) of vector 𝛂 =





⁄ , where 𝒙𝑡𝑒𝑖 and 𝒙𝑡𝑟𝑖 contain samples for the 𝑖-th predictor in the test 
and training sets, respectively, under the assumption of orthogonal design matrices. Now 
revisit Theorem 4.2: it makes sense for negative transfer to be related to the inherent source-
target difference, reflected by 𝛂, and the discrepancy between test and training data of the 
target, reflected by 𝛾𝑖.    
Note that although 𝛂 in unknown in real-world problems, Theorem 4.2 suggests 
that a careful selection of the tuning parameter 𝜆 is needed in order to prevent negative 
transfer. Conventionally, tuning parameter selection favors a full-range search for 𝜆 ∈
[0, 𝑈] , where 0 is the smallest possible number and 𝑈  is the largest number that 
computation can possibly afford or no improvement can be seen by further increasing this 
number. This is based on the rationale that a full-range search has the best chance to find 
the optimal estimator (e.g., “optimal” in terms of minimizing MSPE on a validation set or 
through a LOO cross validation scheme). However, Theorem 4.2 indicates that if the 
optimal 𝜆∗ from the full-range search is greater than 𝜂, there will be negative transfer when 
the trained model is applied to a separate test set. Therefore, choosing a 𝜆 < 𝜆∗ with some 
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sacrifice on the optimality may provide a safe guard against negative transfer, which 
motives the development of P3TL.  
 
4.3.3 P3TL – a TL Model Robust to Negative Transfer 
Based on the theoretical results in Section 4.3.2, we develop a TL model, P3TL, to 
achieve robustness to negative transfer. To properly assess the risk of negative transfer for 
each source patient, we propose to use the one-standard-error (OSE) rule to select the 
tuning parameter 𝜆. This is similar to the OSE rule used in LASSO and smoothing splines 
to give preference over less complex models to avoid overfitting (Friedman, J.H. et al. 
1984; Friedman, J. et al. 2001). Here, we customize the OSE rule to serve the purpose of 
reducing the risk of negative transfer.  
Specifically, for the 𝑗-th source patient, we first identify the set of 𝜆’s, denoted by 
Λ, with which the MSPE of BPT is smaller than that of SL on a validation set, i.e.,  
                       Λ = {𝜆|MSPE𝑣𝑎𝑙(𝜆) < MSPE𝑣𝑎𝑙(0)}.                       (4.10) 
This is the set of BPT models with different tuning parameters but all performing 
better than SL. Note that MSPE𝑣𝑎𝑙 can also be computed using a LOO cross validation 
scheme if the training set is so small that splitting out a validation set is inappropriate. 
Furthermore, we compute the standard deviation of the MSPE𝑣𝑎𝑙(𝜆 ∈ Λ), denoted by 𝜎Λ. 
This reflects the variability of performance improvement of BPT over SL. Among the 
MSPE𝑣𝑎𝑙(𝜆 ∈ Λ), the smallest one corresponds to the optimal 𝜆
∗ from the full-range search, 
i.e., MSPE𝑣𝑎𝑙(𝜆
∗) = min 𝜆∈Λ  MSPE𝑣𝑎𝑙(𝜆). 
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Conventional tuning strategies would use 𝜆∗ as the final parameter. However, based 
on the results from Section 4.3.2, we know that although 𝜆∗ minimizes MSPE𝑣𝑎𝑙, it is likely 
to cause negative transfer on a separate test set. Therefore, we propose to use the OSE rule 
which is based on the notion that any 𝜆 with MSPE𝑣𝑎𝑙(𝜆) greater than MSPE𝑣𝑎𝑙(𝜆
∗) by one 
standard deviation 𝜎Λ should not be considered as statistically significantly different. The 
same notion was adopted in the OSE rule used in LASSO and smoothing splines 
(Friedman, J.H. et al. 1984; Friedman, J. et al. 2001). Within those statistically indifferent 
𝜆’s, we prefer to choose 𝜆 < 𝜆∗ which is less likely to go above the threshold 𝜂 in Theorem 
4.2 to cause negative transfer. To minimize the likelihood of negative transfer, the OSE 
rule goes with the smallest 𝜆 within all that are smaller than 𝜆∗. In summary, selection of 𝜆 
according to the OSE rule can be achieved by solving the following optimization:  
𝜆𝑟
∗ = min 𝜆<𝜆∗,𝜆∈Λ  𝜆 
                                        subject to MSPE𝑣𝑎𝑙(𝜆) ≤ MSPE𝑣𝑎𝑙(𝜆
∗) + 𝜎Λ.                  (4.11) 
Under the OSE-selected tuning parameter in (4.11), we can further assess the 
improvement of transfer learning from each source compared with SL. If the improvement 
is smaller than a threshold 𝛼, this source patient will not be included in the transfer learning 
to the target patient. This source-screening process provides a second layer of safe guard 
against negative transfer. Finally, for the remaining sources, we re-fit a BPT to enable 
transfer learning from these source patients in combination but not others. We use the OSE 
rule in selecting the tuning parameter for this BPT for the same reason mentioned 




In addition, realizing that Algorithm 4.1 does not incorporate the sparsity constraint 
on estimation of 𝐰𝐾, i.e., ‖𝐰𝐾‖1, we develop a sparse version of P3TL, which is more 
suitable for applications with high-dimensional predictors. Adding the sparsity constraint 
results in a model with two tuning parameters, 𝜆1 for sparsity, and 𝜆2 for transfer learning 





The key difference between Algorithm 4.1 and Algorithm 4.2 is that because of the 
addition of one more tuning parameter, i.e., 𝜆1 , we will need to select two tuning 
parameters. This primarily affects the sub-block of “tuning parameter selection using OSE 
rule for each source” in the algorithm. Our current strategy is to search 𝜆1 and 𝜆2 on a 2-D 
grid with 𝜆2  selected following the OSE rule and 𝜆1  searched by following LASSO 
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solution path from the least angle regression (LARS) (Efron, B. et al. 2004). We 
acknowledge two limitations of this strategy: First, since the search will go through every 
point on the grid, computational time increases. Second, even with searching on every grid 
point, the algorithm does not guarantee to find the global optimal solution because the 
problem is not convex with 𝜆1 and 𝜆2 considered as unknown parameters. This challenge 
has also been pointed out by other researchers for general regularized frameworks with 
tuning parameters (Lederer, J. and Müller, C. 2015; Dalalyan, A.S. et al. 2017). Further 
research is needed for tuning parameter selection leading to better optimality while being 
computationally thrifty. 
 
4.4 Simulation Study 
4.4.1 Simulation Experiments for the Non-sparse P3TL Model 
In this section, we use simulation data to demonstrate the performance of non-
sparse P3TL. The simulation data is generated as follows: First, we sample the coefficients 
of each source domain, 𝐰1, from a 𝑁(1,  1) distribution. To create relatedness between the 
target and source domains, we generate the coefficients of the target domain by 𝐰2 = 𝐰1 +
𝛅, where 𝛅 is sampled from 𝑁(0,  𝜎𝛿
2). The size of 𝜎𝛿
2 determines the relatedness between 
the target and source domains; the smaller the 𝜎𝛿
2, the more related the two domains. Next, 
we generate data for the target domain. Data for the 𝑄 predictors are generated from a 
multivariate normal distribution, i.e., 𝐗2~𝑀𝑁(𝟎,𝚺𝑥), where the predictor correlations are 
created by having 𝚺𝑥,𝑖𝑗 = 0.5
|𝑖-𝑗| . 𝚺𝑥,𝑖𝑗  is the covariance between the 𝑖 -th and 𝑗 -th 
predictors. Data for the response variable are generated by 𝑌2 = 𝐗2𝐰2 + 𝜀2, where 𝜀2 is 
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sampled from 𝑁(0,  𝜎𝜀
2). Finally, considering model uncertainty of the source domain, i.e., 
𝐰1 is estimated from finite samples, we use ?̂?1~𝑁(𝐰1,  𝜎1
2𝐈) in the TL model instead of 
the true 𝐰1. The size of 𝜎1
2 determines the level of uncertainty in the model/knowledge 
transferred from the source domain to the target domain.  
We consider 20 predictors and 50 samples in the training, validation, and test sets, 
respectively. We set 𝜎𝛿
2 to range from 1 to 100 to represent different levels of relatedness 
between the target and source domains, and set 𝜎1
2 to range from 1 to 100 to represent 
different levels of uncertainty in the model/knowledge of the source domains. We consider 
100 source domains to potentially transfer from, and apply the non-sparse version of P3TL. 
The non-sparse version is appropriate because the sample size well exceeds the number of 
predictors. We leave the demonstration of the sparse version of P3TL to the next section.  
We consider two competing TL methods: the 1st method is ignorant about the risk 
of negative transfer so it transfers from all available sources using BPT. Call this method 
“baseline TL”. The 2nd competing method has some level of awareness for negative transfer 
so it performs source-screening like P3TL, but uses a full-range search for the optimal 
tuning parameter instead of the OSE rule. Call this method “TL with full-range search”. 
We compare the three TL methods in terms of the following metrics: 1) percentage of 
negative transfer, for which we compare the MSPE of a TL method and that of SL on the 
test set, and compute the percentage of times that the former MSPE exceeds the latter; 2) 
average reduction of MSPE over SL on the test set.  
There is one parameter for P3TL, 𝛼, which is the threshold for source screening, 
i.e., a source patient will not be included in transfer learning to the target if the MSPE by 
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using BPT under the OSE rule improves over SL by a percentage smaller than 𝛼. We 
choose 𝛼 = 10% in our experiments while other values show similar trends. The results 




We can draw the following observations: First, Figure. 14 (a) and (b) show the 
performance comparison when the target and source have varying levels of relatedness, 
Figure. 14. (a) Percentage of negative transfer, and (b) average reduction of MSPE 
over SL on the test set with varying 𝜎𝛿
2 values under 𝜎1

































































































































Figure. 15. (a) Percentage of negative transfer, and (b) average reduction of MSPE 
over SL on the test set with varying 𝜎1
2 values under 𝜎𝛿




2 = 0  representing that the target and source have exactly the same model 
coefficients. The larger the 𝜎𝛿
2, the less similar between the target and the source. It can be 
seen that P3TL outperforms the two competing methods in terms of having a lower 
percentage of negative transfer (Figure. 14(a)) and a larger average reduction of MSPE 
over SL (Figure. 14(b)). The outperformance of P3TL is more significant with larger 𝜎𝛿
2, 
i.e., when the target and source are less similar. The 1st competing method, i.e., baseline 
TL, in general performs the worst because it does not have any safe guard against negative 
transfer. The 2nd competing method, i.e., TL with full-range search, performs source 
screening like P3TL, which provides a chance to exclude dissimilar sources from transfer 
learning to the target. However, its performance is still worse than P3TL because it adopts 
full-range search for the tuning parameter, which runs the risk of negative transfer. This 
implies the importance of the OSE rule in P3TL for preventing negative transfer. 
Second, Figure 15 (a) and (b) show the performance comparison with varying levels 
of uncertainty in the model/knowledge of the source, with 𝜎1
2 = 0  representing zero 
uncertainty, i.e., the source model coefficients used in transfer learning are the true 
coefficients. Larger 𝜎1
2 means higher likelihood for the source model coefficients to be 
different from the true coefficients due to reasons like sampling uncertainty.  It can be seen 
that P3TL outperforms the two competing methods in terms of having a lower percentage 
of negative transfer (Figure 15 (a)) and a larger average reduction of MSPE over SL (Figure 
15 (b)). The outperformance of P3TL is more significant with larger 𝜎1
2, i.e., when there is 
more uncertainty in the source model coefficients. This result further demonstrates the 
robustness of P3TL to negative transfer against uncertain/noisy source domain knowledge. 
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4.4.2 Simulation Experiments for the Sparse P3TL Model 
In this section, we generate simulation data to demonstrate the performance of 
sparse P3TL in Algorithm 4.2. We consider 100 predictors with 10 having nonzero 
coefficients in the source domain. The nonzero coefficients, ?̃?1 , are sampled from a 
𝑁(5,  1) , and then padded with zeros to make up 𝐰1 . Let ?̃?2 = ?̃?1 + 𝛅 , where 𝛅  is 
sampled from 𝑁(0,  𝜎𝛿
2). Compose coefficients of the target domain, 𝐰2, by padding ?̃?2 
with almost all zero coefficients except one sampled from 𝑁(0,  1). This is to create a more 
general simulation setting by allowing the target and source domains to have different 
predictors with nonzero coefficients. Next, we generate data of the predictors and response 
for the target domain in the same way as the non-sparse experiments in Section 4.3.1. To 
create a “small-n-large-p” scenario for sparse models, we include 20 samples in the 
training, validation, and test sets, respectively. Finally, considering model uncertainty of 
the source domain, we replace ?̃?1 by ?̂̃?1~𝑁(?̃?1,  𝜎1
2𝐈) in the coefficients of the source 
domain.  
We set 𝜎𝛿
2 to range from 1 to 20 to represent different levels of relatedness between 
the target and source domains, and set 𝜎1
2 to range from 1 to 20 to represent different levels 
of uncertainty in the model/knowledge of the source domains. We consider 100 source 
domains to potentially transfer from, and apply the sparse version of P3TL. The results are 
shown in Figure 16 and 17. Similar observations to the non-sparse experiments can be 
drawn, which show that P3TL outperforms the two competing methods in terms of having 
a lower percentage of negative transfer and a larger average reduction of MSPE over SL 
across the different values for 𝜎𝛿
2 (Figure 16) and  𝜎1






4.5 Application in Telemonitoring of Parkinson’s Disease (PD) 
In this section, we present the application of P3TL on predicting the UPDRS of PD 
patients using their voice signals measured by the telemonitoring device AHTD. AHTD 
initializes a recording by audible instruction to the patient. This is followed by a “beep” 
which cues the patient to begin sustained phonation of the vowel “ahhh…”. The voice 
Figure 16. (a) Percentage of negative transfer, and (b) average reduction of MSPE over 
SL on the test set with varying 𝜎𝛿
2 values under 𝜎1
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Figure. 17. (a) Percentage of negative transfer, and (b) average reduction of MSPE over 
SL on the test set with varying 𝜎1
2 values under 𝜎𝛿
2 = 5 
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signal is being captured for 30 seconds or once the detected signal amplitude drops below 
a threshold, whichever happens sooner.  
We use the data collected by a study joined performed by the University of Oxford 
in collaboration with 10 medical centers in the U.S. and Intel Corporation. 42 early-stage 
PD patients were recruited. Sustained vowel phonation was measured weekly by each 
patient using AHTD at home. The digital signal of each sustained vowel phonation was 
processed by several classical speech signal processing algorithms and 16 features, called 
“dysphonia measures”, were extracted. The features included measures of variation in 
fundamental frequency, amplitude, ratios of noise to tonal components, nonlinear dynamic 
complexity, signal fractal scaling exponent, and nonlinear fundamental frequency variation. 
Figure 18 shows distributions of the 16 features in the 42 patients. Also, UPDRS of each 
patient was administered at one of the six medical centers involved in this study at baseline, 
three months, and six months. UPDRS is an instrument used to rate PD severity, which 
consists of 42 items measuring effects of the disease on a patient's activities of daily living, 
behavior, mentation, mood, movement, and so on. We use the UPDRS total score in this 
study, which ranges from 0 to 176, with 0 corresponding to a health status and 176 as total 
disability. Weekly UPDRS values were obtained by linear interpolation. A linear trend of 
UPDRS as PD progresses has been validated in a number of previous studies (Dorsey, E. 
et al. 2007; Tsanas, A. et al. 2010; Chan, P.L.S. and Holford, N.H.G. 2001; Schüpbach, 
W.M.M. et al. 2010). The data was downloaded from the UCI repository.  
In applying P3TL, each patient is considered the target and all other patients as the 
sources. Each patient has 101-168 samples, which are divided into a training, validation, 
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and test set. Predictors (dysphonia measures) are standardized using the sample means and 
sample standard deviations of the training set. Knowledge about each source patient is 
provided in the form of regression coefficients estimated using the respective data from 
that patient. 
 
Figure 18: Histograms of 16 dysphonia measures in our dataset (x axis: range of the 
measure; y axis: frequency of observations falling into each histogram bin) 
 
 
The non-sparse P3TL algorithm is used because the predictors include 16 
dysphonia measures which are not many. We are particularly interested in finding how the 
training sample size affects P3TL performance, because the size is related to how soon a 
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using 10-90% of the total samples with 10% increment for each patient. We compare the 
performance of P3TL with two competing TL methods that were also used in simulation 
studies (Zou, N. et al. 2015). We report the absolute prediction error on test data for the 
three TL methods in Figure 19. P3TL outperforms the two competing methods across all 




Furthermore, we compare the performance of P3TL in comparison with SL, which 
builds a predictive model using data of the target patient alone, and with one-model-fits-
all (OMFA), which pools the data of all patients together and builds a single model for all 
patients. In the SL and the OMFA approaches, we try different predictive models including 
linear regression, Gaussian process (GP) regression, regression tree, ensemble regression 
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Figure. 19: Performance comparison between three TL methods with the different 
training sample sizes 
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each competing method. Figure 20 shows the absolute prediction error on test data 
averaged over all the patients for each method.  It is clear that P3TL outperforms all the 
competing methods by having a smaller prediction error. Between OMFA and SL, OMFA 
models significantly underperform SL models in this application due to the heterogeneity 








Figure 20: Absolute prediction error on test data averaged over all the patients for 































CONCLUSIONS AND FUTURE WORK 
 
Technological advances in diagnostic imaging, Electronic Health Records (EHR), 
and remote and smart sensing have created a data-rich environment in smart and health 
connected systems. These system offers a great opportunity toward the right medical 
treatment for the right person at the right time, which is called precision medicine. The key 
challenge in achieving precision medicine in health care applications is patients’ 
heterogeneity. Every patient is different so a patient-specific model needs to be trained. 
However, the model suffers from limited sample size due to the small number of samples 
included in the training set. Transfer learning is a desirable approach to leverage other 
patients’ information to integrate with each target patient’s specific data. In my dissertation, 
I focused on developing three novel transfer learning algorithms for addressing limitations 
of existing methods. In collaboration with health care domain experts, my research has 
explored a few health care applications, especially telemonitoring and radiomics. 
For the telemonitoring of PD, I proposed a new method (METL) to better discover 
similarity and heterogeneity across patients. This model has the capability of 
telemonitoring even with few samples, as well as adaptability of more available samples 
per patient for a better opportunity to detect and quantify the movement disorder of PD 
patients. The next topic focused on the MRI-based transfer learning algorithm for non-
invasive surgical guidance of glioblastoma patients. The MRI-based TL model generates 
individualized patient models, grounded in the wealth of population data, while also 
detecting and adjusting for interpatient variabilities based on each patient’s own histologic 
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data. Incorporating domain knowledge into the TL model helps to significantly improve 
performance for quantifying tumor cell density in glioblastoma. Lastly, driven by the 
theoretical insights, I developed a new TL method, P3TL. The unique features of P3TL 
include intelligent selection of patients to transfer in order to avoid negative transfer and 
maintain patient privacy preservation. This work addresses privacy concerns in health care 
domains and provides accurate predictions. 
For the future work, I would like to consider an extension of TL methods from a smart-
sensing data. A new framework can incorporate data directly from multiple sensors into TL 
models instead of incorporating features from signal data. It can also be extended to semi-
supervised active learning with iterative physician involvement for augmented intelligence. 
Additional future directions include extension of proposed methods to model nonlinear 
predictive relationships using kernels; applications on other disease domains; and 
evaluation using various real-world datasets even outside the health domain since negative 
transfer is a common problem when TL is used. Lastly, there are enormous data science 
challenges to be tackled in order to best leverage the existing data resources, imaging, mobile 
sensing, and video recording data. I would like to develop novel machine learning models to 
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Proof of Theorem 4.1 To prove Theorem 1, we need the following lemma 4.1.   
Lemma 4.1. Let 𝑺 denote a training set for a target patient. Let ?̂?𝑲 and ?̂?𝑺\𝒊 be the 
model coefficients of 𝒇𝑺 and 𝒇𝑺\𝒊 , respectively. Then, we have the following bounds:  
   E𝑆[(?̂?𝐾 − 𝛍𝐾)
𝑇(?̂?𝐾 − 𝛍𝐾)] ≤
MSPE(𝛍𝐾) 
𝜆
,                (4.13) 
                                      E𝑆 [(?̂?𝑆\𝑖 − 𝛍𝐾)
𝑇
(?̂?𝑆\𝑖 − 𝛍𝐾)] ≤
MSPE(𝛍𝐾) 
𝜆
.                            (4.14) 
 
Proof of Lemma 1: From BPT objective function in (4.7), 





2 + 𝜆((𝐰𝑆 − 𝛍𝐾)
𝑇(𝐰𝑆 − 𝛍𝐾)), 
we have  




2 = MSPÊ(𝛍𝐾).                 (4.15) 
Using the fact that 𝜆(?̂?𝑆 − 𝛍𝐾)





2 + 𝜆(?̂?𝑆 − 𝛍𝐾)
𝑇(?̂?𝑆 − 𝛍𝐾), 
we get 𝜆(?̂?𝑆 − 𝛍𝐾)
𝑇(?̂?𝑆 − 𝛍𝐾) ≤ MSPÊ(𝛍𝐾).                                                            (4.16) 
When 𝜆 ≠ 0, (?̂?𝑆 − 𝛍𝐾)
𝑇(?̂?𝑆 − 𝛍𝐾) ≤
MSPÊ(𝛍𝐾) 
𝜆








 . This proves the bound in (4.13). Furthermore, to prove 
(4.14), we can follow a similar procedure and get 
                                           Q(?̂?𝑆\𝑖) ≤ Q(𝛍𝐾) =
1
𝑛𝑡𝑟−1




𝑗≠𝑖 .                     (4.17) 
When 𝜆 ≠ 0,  
(?̂?𝑆\𝑖 − 𝛍𝐾)
𝑇
(?̂?𝑆\𝑖 − 𝛍𝐾) ≤
1
𝜆(𝑛𝑡𝑟−1)




𝑗≠𝑖 . This leads to 
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E𝑆 [(?̂?𝑆\𝑖 − 𝛍𝐾)
𝑇















 .                                           ∆ 
In order to derive the generalization bound in this Theorem, we will first need to 
introduce the concepts of hypothesis stability and polynomial bound introduced by 
Bousquet, O. and Elisseeff, A. (2002). An algorithm has a hypothesis stability γ if 
 
                                        E𝑆,(𝐗,𝐲)[|𝑙(𝑓𝑆(𝐗), 𝑦) − 𝑙(𝑓𝑆\𝑖(𝐗), 𝑦)|] ≤ 𝛾                            (4.18) 
With 𝛾 and M such that 𝑙(𝑓𝑆\𝑖(𝒙𝑖, 𝑦𝑖)) ≤ M  for any 𝑖 ∈ {1,2, … , 𝑛𝑡𝑟} , the polynomial 
bound of an algorithm is 





+ 3M𝛾                     (4.19) 
In our case, the predictive function 𝑓 is BPT and the loss function 𝑙 is MSPE. Therefore, 
we will need to identify 𝛾 and M in (4.18) and (4.19) under the specific BPT model and 
MSPE loss, which will further lead us to derive the generalization bound. We will present 
the derivations in three steps: 
1) Derive 𝛾 
Under the BPT model, the left side of (4.18) becomes 
E𝑆,(𝐗,𝐲) [|(𝐗?̂?𝑆 − 𝐲)
𝟐 − (𝐗?̂?𝑆\𝑖 − 𝐲)
𝟐
|]  
= E𝑆,(𝐗,𝐲) [|(𝐗(?̂?𝑆 − 𝛍𝐾 + 𝛍𝐾) − 𝐲)





= E𝑆,(𝐗,𝐲) [|(𝐗(?̂?𝑆 − 𝛍𝐾) − (𝐲 − 𝐗𝛍𝐾))
𝟐 − (𝐗(?̂?𝑆\𝑖 − 𝛍𝐾) − (𝐲 − 𝐗𝛍𝐾))
𝟐
|]              (4.20) 
Using the fact that |(a − 𝑐)2 − (b − c)2| ≤ (a − b)2 + 2|(b − 𝑐)(a − b)| , (4.20) 
becomes: 
E𝑆,(𝐗,𝐲) [|(𝐗?̂?𝑆 − 𝐲)
𝟐 − (𝐗?̂?𝑆\𝑖 − 𝐲)
𝟐
|] 
≤ E𝑆,(𝐗,𝐲) [(𝐗(?̂?𝑆 − 𝛍𝐾) − 𝐗(?̂?𝑆\𝑖 − 𝛍𝐾))
𝟐
] + 
2√E𝑆,(𝐗,𝐲) [(𝐗(?̂?𝑆 − 𝛍𝐾) − 𝐗(?̂?𝑆\𝑖 − 𝛍𝐾))
𝟐
] ×  
√E𝑆,(𝐗,𝐲)[(𝐗(?̂?𝑆\𝑖 − 𝛍𝐾) − (𝐲 − 𝐗𝛍𝐾))
𝟐].                                                                                (4.21) 
Next, we want to find bounds for the two different terms in (4.21), i.e.,  
        E𝑆,(𝐗,𝐲) [(𝐗(?̂?𝑆 − 𝛍𝐾) − 𝐗(?̂?𝑆\𝑖 − 𝛍𝐾))
𝟐
],                                        (4.22)  
         E𝑆,(𝐗,𝐲) [(𝐗(?̂?𝑆\𝑖 − 𝛍𝐾) − (𝐲 − 𝐗𝛍𝐾))
𝟐
].                                    (4.23) 
For the bound of (4.22), we follow the Lemma 1 from (Kuzborskij, I. and Orabona, F. 
2013), and get ‖𝐗?̂?𝑆 − 𝐗?̂?𝑆\𝑖‖ ≤
1
𝑛𝑡𝑟𝜆
‖𝒙𝑖?̂?𝑆\𝑖 − 𝒚𝑖‖. Using this inequality in (4.21), we 
can get 







E𝑆 [(𝒙𝑖(?̂?𝑆\𝑖 − 𝛍𝐾) − (𝒚𝑖 − 𝒙𝑖𝛍𝐾))
𝟐








+ (𝒚𝑖 − 𝒙𝑖𝛍𝐾)





(E𝑆 [‖?̂?𝑆\𝑖 − 𝛍𝐾‖
2
] + E𝑆[(𝒚𝑖 − 𝒙𝑖𝛍𝐾)


















+ 1)                                                                                                     (4.24) 
in which the 2nd step uses Cauchy-Schwarz inequality, the 3rd step uses Jensen’s inequality, 
and the 4th step uses Lemma 4.1. 
For the bound of (4.23), we will also use Cauchy-Schwarz Jensen’s inequality, and Lemma 
4.1 as well and get 
E𝑆 [(𝐗(?̂?𝑆\𝑖 − 𝛍𝐾) − (𝐲 − 𝐗𝛍𝐾))
𝟐
] 
≤ 2E𝑆 [(𝐗(?̂?𝑆\𝑖 − 𝛍𝐾))
𝟐





] + E𝑆[(𝐲 − 𝐗𝛍𝐾)
𝟐])  
≤ 2(E𝑆 [‖?̂?𝑆\𝑖 − 𝛍𝐾‖
2









+ 1).                                                                                                             (4.25) 
Plugging (4.24) and (4.25) into (4.21), we can get 𝛾, i.e., 













+ 1)                             (4.26) 
2) Derive M 
The process of deriving M is similar to that deriving 𝛾, and is therefore skipped. Here 
we only present the brief steps and result: 





≤ 2 [(𝒙𝑖(?̂?𝑆\𝑖 − 𝛍𝐾))
𝟐









+ 1)= M.                                                                                           (4.27) 
3) Derive the generalization bound 
Putting (4.26) and (4.27) into (4.19), we have get 







































(12 + 24𝑛𝑡𝑟𝜆 + 2𝑛𝑡𝑟𝜆
2).                                (4.28) 
According to Chebyshev’s inequality, P[𝑋 ≥ 𝜖] ≤
E[𝑋2]
𝜖2




probability at least 1 − δ for δ > 0. Using this property, we can get the generalization 
bound from (4.28), i.e.,  









.           ∆ 
 
Proof of Theorem 4.2 
To prove Theorem 4.2, we need the following lemmas.   
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𝑻 𝑿𝒗𝒂𝒍 = 𝒅𝒊𝒂𝒈(𝜸𝒗𝒂𝒍𝟏 , … , 𝜸𝒗𝒂𝒍𝑸). 
Then, the MSPE on the validation set is 









𝑖=1 .                            (4.29) 
Proof of Lemma 4.2: According to the definition of MSPE, 







𝑇 ?̂?𝐾(𝜆))},                          (4.30) 
where ?̂?𝐾(𝜆)  is the optimal solution to (4.7) using the training set, i.e., ?̂?𝐾(𝜆) =
(𝐗𝑡𝑟
𝑇 𝐗𝑡𝑟 + 𝑛𝑡𝑟λ𝐈)
−1(𝐗𝑡𝑟
𝑇 𝐲𝑡𝑟 + 𝑛𝑡𝑟λ𝛍𝐾). For notation simplicity, we omit the “(𝜆)” and use 
?̂?𝐾  to represent ?̂?𝐾(𝜆)  in the following derivations. Using an algebra trick, (4.30) 
becomes:   
MSPE𝑣𝑎𝑙(𝜆) 
= E{(𝐲𝑣𝑎𝑙 − 𝐗𝑣𝑎𝑙
𝑇 𝐰𝐾 + 𝐗𝑣𝑎𝑙
𝑇 𝐰𝐾 − 𝐗𝑣𝑎𝑙
𝑇 ?̂?𝐾)
𝑇(𝐲𝑣𝑎𝑙 − 𝐗𝑣𝑎𝑙
𝑇 𝐰𝐾 + 𝐗𝑣𝑎𝑙
𝑇 𝐰𝐾 − 𝐗𝑣𝑎𝑙
𝑇 ?̂?𝐾)}/𝑛𝑣𝑎𝑙 






𝑇 𝐗𝑣𝑎𝑙(?̂?𝐾 −𝐰𝐾)}/𝑛𝑣𝑎𝑙 
                           −2E{(𝐲𝑣𝑎𝑙 − 𝐗𝑣𝑎𝑙
𝑇 𝐰𝐾)
𝑇𝐗𝑣𝑎𝑙
𝑇 (?̂?𝐾 −𝐰𝐾)}/𝑛𝑣𝑎𝑙.                                 (4.31)                     
The first term (4.31) is 𝜎2, where 𝑛𝑣𝑎𝑙 is the sample size in the validation set and 𝜎
2 is the 
residual variance of the regression model. The last term becomes 2E{ε𝑣𝑎𝑙
T X𝑣𝑎𝑙
𝑇 (ŵ𝐾 −
w𝐾)} = 0. Therefore, (4.31) becomes:  
MSPE𝑣𝑎𝑙(𝜆) = 𝜎
2 + E{(?̂?𝐾 −𝐰𝐾)
𝑇𝐗𝑣𝑎𝑙
𝑇 𝐗𝑣𝑎𝑙(?̂?𝐾 −𝐰𝐾)}/𝑛𝑣𝑎𝑙.                              (4.32)  
To carry on the derivation, let ?̌?𝐾 be the SL estimator using the training set, i.e., 
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?̌?𝐾  is the ?̂?𝐾  when 𝜆 = 0 . Also define 𝐁 = (𝐗𝑡𝑟
𝑇 𝐗𝑡𝑟 + 𝑛𝑡𝑟λ𝐈𝑄)
−1





𝑇 𝐗𝑡𝑟. Using 𝐁 and 𝐙, we can show that ?̂?𝐾 = 𝐙?̌?𝐾 + 𝑛𝑡𝑟λ𝐁𝛍𝐾. Inserting this 
into (4.32), we get: 
MSPE𝑣𝑎𝑙(𝜆) = 𝜎
2
+ E{(𝐙?̌?𝐾 + 𝑛𝑡𝑟λ𝐁𝛍𝐾 −𝐰𝐾)
𝑇𝐗𝑣𝑎𝑙
𝑇 𝐗𝑣𝑎𝑙(𝐙?̌?𝐾 + 𝑛𝑡𝑟λ𝐁𝛍𝐾 −𝐰𝐾)}/𝑛𝑣𝑎𝑙 
= 𝜎2 + E{(𝐙?̌?𝐾 − 𝐙𝐰𝐾 + 𝐙𝐰𝐾 + 𝑛𝑡𝑟λ𝐁𝛍𝐾 −𝐰𝐾)
𝑇𝐗𝑣𝑎𝑙
𝑇 𝐗𝑣𝑎𝑙 
   (𝐙?̌?𝐾 − 𝐙𝐰𝐾 + 𝐙𝐰𝐾 + 𝑛𝑡𝑟λ𝐁𝛍𝐾 −𝐰𝐾).                                              (4.33) 
To further simplify (4.33), we utilize the relationship that 𝐙 = 𝐈 − 𝑛𝑡𝑟λ𝐁. Multiplying 
both sides of this equation by 𝐰𝐾 , we get 𝐙𝐰𝐾 = 𝐰𝐾 − 𝑛𝑡𝑟λ𝐁𝐰𝐾 . Then, the 𝐙𝐰𝐾 +
𝑛𝑡𝑟λ𝐁𝛍𝐾 −𝐰𝐾 in (4.33) becomes 𝑛𝑡𝑟λ𝐁𝛍𝐾 − 𝑛𝑡𝑟λ𝐁𝐰𝐾. Inserting this back to (4.33), we 
get  
MSPE𝑣𝑎𝑙(𝜆) 
= 𝜎2 +  E{(?̌?𝐾 −𝐰𝐾)
𝑇𝐙𝑇𝐗𝑣𝑎𝑙




𝑇 𝐗𝑣𝑎𝑙𝐁(𝛍𝐾 −𝐰𝐾) 






𝑇 𝐗𝑣𝑎𝑙𝐁(𝛍𝐾 −𝐰𝐾) 
= 𝜎2 + 𝜎2𝑡𝑟{(𝐗𝑡𝑟
𝑇 𝐗𝑡𝑟)
−1𝐙𝑇𝐗𝑣𝑎𝑙
𝑇 𝐗𝑣𝑎𝑙𝐙} + 𝑛𝑡𝑟
2 𝜆2(𝛍𝐾 −𝐰𝐾)
𝑇𝐁𝑇𝐗𝑣𝑎𝑙
𝑇 𝐗𝑣𝑎𝑙𝐁(𝛍𝐾 −𝐰𝐾) 
  = 𝜎2 + 𝜎2𝑡𝑟{𝐁𝐙𝑇𝐗𝑣𝑎𝑙
𝑇 𝐗𝑣𝑎𝑙} + 𝑛𝑡𝑟
2 𝜆2(𝛍𝐾 −𝐰𝐾)
𝑇𝐁𝑇𝐗𝑣𝑎𝑙
𝑇 𝐗𝑣𝑎𝑙𝐁(𝛍𝐾 −𝐰𝐾) 
= 𝜎2 + 𝜎2𝑡𝑟{𝐁(𝐈 − 𝑛𝑡𝑟λ𝐁)𝐗𝑣𝑎𝑙
𝑇 𝐗𝑣𝑎𝑙} + 𝑛𝑡𝑟
2 𝜆2(𝛍𝐾 −𝐰𝐾)
𝑇𝐁𝑇𝐗𝑣𝑎𝑙
𝑇 𝐗𝑣𝑎𝑙𝐁(𝛍𝐾 −𝐰𝐾) 
  = 𝜎2 + 𝜎2𝑡𝑟{𝐁𝐗𝑣𝑎𝑙
𝑇 𝐗𝑣𝑎𝑙} − 𝑛𝑡𝑟𝜆𝜎
2𝑡𝑟{𝐁2𝐗𝑣𝑎𝑙
𝑇 𝐗𝑣𝑎𝑙}       
       + 𝑛𝑡𝑟
2 𝜆2(𝛍𝐾 −𝐰𝐾)
𝑇𝐁𝑇𝐗𝑣𝑎𝑙























𝑖=1 .                  ∆ 
 




𝑻 𝐗𝒕𝒆 = 𝒅𝒊𝒂𝒈(𝜸𝒕𝒆𝟏 , … , 𝜸𝒕𝒆𝑸). Then, the MSPE on the test set is 









𝑖=1 .                 (4.35) 
The proof of Lemma 4.3 is similar that of Lemma 4.2 and therefore skipped.  
 
Without loss of generality, we assume 𝛾𝑡𝑟𝑖 = 1. This means that model training will 
use “normalized” data in which the original samples of the 𝑖-th predictor are divided by 
‖𝒙𝑡𝑟𝑖‖2
2
. For consistency, ‖𝒙𝑡𝑟𝑖‖2
2





⁄ . Then, (4.35) becomes 








𝑖=1                                  (4.36) 
Finally, using the results of Lemma 4.2 and Lemma 4.3, we can further derive the 
condition under which negative transfer will happen:  
 






















𝑖=1 − 𝜆∑ 𝛾𝑖𝜎
2𝑄
𝑖=1 − 2∑ 𝛾𝑖𝜎
2𝑄










𝑖=1 − 2∑ 𝛾𝑖𝜎
2𝑄












which concludes the proof.                                                       ∆ 
 
